US20210347890A1 - Cd31shed as a molecular target for imaging of inflammation - Google Patents
Cd31shed as a molecular target for imaging of inflammation Download PDFInfo
- Publication number
- US20210347890A1 US20210347890A1 US17/305,966 US202117305966A US2021347890A1 US 20210347890 A1 US20210347890 A1 US 20210347890A1 US 202117305966 A US202117305966 A US 202117305966A US 2021347890 A1 US2021347890 A1 US 2021347890A1
- Authority
- US
- United States
- Prior art keywords
- peptide
- amino acids
- seq
- shed
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000003384 imaging method Methods 0.000 title claims abstract description 78
- 230000004054 inflammatory process Effects 0.000 title abstract description 48
- 206010061218 Inflammation Diseases 0.000 title abstract description 46
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 178
- 239000003446 ligand Substances 0.000 claims abstract description 160
- 150000001413 amino acids Chemical class 0.000 claims description 208
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 42
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 37
- 239000012634 fragment Substances 0.000 claims description 31
- 150000001875 compounds Chemical class 0.000 claims description 22
- 238000002600 positron emission tomography Methods 0.000 claims description 20
- HBBSDZXXUIHKJE-UHFFFAOYSA-N 6-hydrazinylpyridine-3-carboxylic acid Chemical compound NNC1=CC=C(C(O)=O)C=N1 HBBSDZXXUIHKJE-UHFFFAOYSA-N 0.000 claims description 17
- 238000007385 chemical modification Methods 0.000 claims description 10
- 239000000816 peptidomimetic Substances 0.000 claims description 9
- GYHNNYVSQQEPJS-OIOBTWANSA-N Gallium-67 Chemical compound [67Ga] GYHNNYVSQQEPJS-OIOBTWANSA-N 0.000 claims description 8
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 8
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 claims description 8
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 claims description 8
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 claims description 8
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 claims description 8
- 229940056501 technetium 99m Drugs 0.000 claims description 8
- BKVIYDNLLOSFOA-OIOBTWANSA-N thallium-201 Chemical compound [201Tl] BKVIYDNLLOSFOA-OIOBTWANSA-N 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- GYHNNYVSQQEPJS-YPZZEJLDSA-N Gallium-68 Chemical compound [68Ga] GYHNNYVSQQEPJS-YPZZEJLDSA-N 0.000 claims description 6
- 229940006110 gallium-67 Drugs 0.000 claims description 4
- 229940055742 indium-111 Drugs 0.000 claims description 4
- RYGMFSIKBFXOCR-IGMARMGPSA-N copper-64 Chemical compound [64Cu] RYGMFSIKBFXOCR-IGMARMGPSA-N 0.000 claims description 3
- 108091023037 Aptamer Proteins 0.000 claims description 2
- KRHYYFGTRYWZRS-BJUDXGSMSA-N ac1l2y5h Chemical compound [18FH] KRHYYFGTRYWZRS-BJUDXGSMSA-N 0.000 claims description 2
- LQRJAEQXMSMEDP-XCHBZYMASA-N peptide a Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)NCCCC[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C/C=1C=CC=CC=1)C(N)=O)C(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C\C1=CC=CC=C1 LQRJAEQXMSMEDP-XCHBZYMASA-N 0.000 claims description 2
- 230000004968 inflammatory condition Effects 0.000 abstract description 102
- 210000004027 cell Anatomy 0.000 abstract description 43
- 239000012216 imaging agent Substances 0.000 abstract description 27
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 23
- 230000002757 inflammatory effect Effects 0.000 abstract description 11
- 238000011552 rat model Methods 0.000 abstract description 5
- 210000000056 organ Anatomy 0.000 abstract description 4
- 210000003040 circulating cell Anatomy 0.000 abstract description 2
- 235000001014 amino acid Nutrition 0.000 description 198
- 238000000034 method Methods 0.000 description 64
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 46
- 102000004196 processed proteins & peptides Human genes 0.000 description 25
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 23
- 239000007997 Tricine buffer Substances 0.000 description 23
- 239000012472 biological sample Substances 0.000 description 23
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 23
- 230000027455 binding Effects 0.000 description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 125000003275 alpha amino acid group Chemical group 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 16
- 238000012544 monitoring process Methods 0.000 description 16
- 208000002223 abdominal aortic aneurysm Diseases 0.000 description 14
- 208000007474 aortic aneurysm Diseases 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 210000003141 lower extremity Anatomy 0.000 description 14
- 230000004807 localization Effects 0.000 description 13
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 210000002889 endothelial cell Anatomy 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 239000002738 chelating agent Substances 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- 210000000265 leukocyte Anatomy 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 239000000700 radioactive tracer Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 102000035195 Peptidases Human genes 0.000 description 8
- 108091005804 Peptidases Proteins 0.000 description 8
- -1 ammonium tetrathiomolybdate anion Chemical class 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000002372 labelling Methods 0.000 description 8
- 125000006850 spacer group Chemical group 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 235000019833 protease Nutrition 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 150000008574 D-amino acids Chemical class 0.000 description 6
- 241001529936 Murinae Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000004007 reversed phase HPLC Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000001772 blood platelet Anatomy 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000005755 formation reaction Methods 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 208000026278 immune system disease Diseases 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 229950009151 mertiatide Drugs 0.000 description 5
- 201000006417 multiple sclerosis Diseases 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 4
- RXACEEPNTRHYBQ-UHFFFAOYSA-N 2-[[2-[[2-[(2-sulfanylacetyl)amino]acetyl]amino]acetyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)CNC(=O)CNC(=O)CS RXACEEPNTRHYBQ-UHFFFAOYSA-N 0.000 description 4
- 206010002329 Aneurysm Diseases 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 4
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 239000001293 FEMA 3089 Substances 0.000 description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
- 150000008575 L-amino acids Chemical class 0.000 description 4
- 230000021736 acetylation Effects 0.000 description 4
- 238000006640 acetylation reaction Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000010933 acylation Effects 0.000 description 4
- 238000005917 acylation reaction Methods 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000002612 dispersion medium Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 102000046661 human PECAM1 Human genes 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- IVWWFWFVSWOTLP-YVZVNANGSA-N (3'as,4r,7'as)-2,2,2',2'-tetramethylspiro[1,3-dioxolane-4,6'-4,7a-dihydro-3ah-[1,3]dioxolo[4,5-c]pyran]-7'-one Chemical compound C([C@@H]1OC(O[C@@H]1C1=O)(C)C)O[C@]21COC(C)(C)O2 IVWWFWFVSWOTLP-YVZVNANGSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000021642 Muscular disease Diseases 0.000 description 3
- 201000009623 Myopathy Diseases 0.000 description 3
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 210000000702 aorta abdominal Anatomy 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229960003330 pentetic acid Drugs 0.000 description 3
- 238000000163 radioactive labelling Methods 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 230000001732 thrombotic effect Effects 0.000 description 3
- SNUSZUYTMHKCPM-UHFFFAOYSA-N 1-hydroxypyridin-2-one Chemical compound ON1C=CC=CC1=O SNUSZUYTMHKCPM-UHFFFAOYSA-N 0.000 description 2
- 206010003178 Arterial thrombosis Diseases 0.000 description 2
- 208000023328 Basedow disease Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- ZWQROOGTEZMFNX-UHFFFAOYSA-N CC(=O)C(CCCCN)NC(=O)CCOCCOCCOCCCC(=O)C1=CN=C(CN)C=C1 Chemical compound CC(=O)C(CCCCN)NC(=O)CCOCCOCCOCCCC(=O)C1=CN=C(CN)C=C1 ZWQROOGTEZMFNX-UHFFFAOYSA-N 0.000 description 2
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 229910052688 Gadolinium Inorganic materials 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 102000016387 Pancreatic elastase Human genes 0.000 description 2
- 108010067372 Pancreatic elastase Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 241000605862 Porphyromonas gingivalis Species 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 208000035868 Vascular inflammations Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 2
- 235000008206 alpha-amino acids Nutrition 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 239000012062 aqueous buffer Substances 0.000 description 2
- 230000007214 atherothrombosis Effects 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000008247 brain infarction Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- IUTCEZPPWBHGIX-UHFFFAOYSA-N tin(2+) Chemical compound [Sn+2] IUTCEZPPWBHGIX-UHFFFAOYSA-N 0.000 description 2
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 description 1
- 229940006190 2,3-dimercapto-1-propanesulfonic acid Drugs 0.000 description 1
- JLVSRWOIZZXQAD-UHFFFAOYSA-N 2,3-disulfanylpropane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(S)CS JLVSRWOIZZXQAD-UHFFFAOYSA-N 0.000 description 1
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- IDOGEHIWMJMAHT-BYPYZUCNSA-N Gly-Gly-Cys Chemical compound NCC(=O)NCC(=O)N[C@@H](CS)C(O)=O IDOGEHIWMJMAHT-BYPYZUCNSA-N 0.000 description 1
- PDAWDNVHMUKWJR-ZETCQYMHSA-N Gly-Gly-His Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 PDAWDNVHMUKWJR-ZETCQYMHSA-N 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 108010036650 Immunoproteins Proteins 0.000 description 1
- 102000012214 Immunoproteins Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000006852 aliphatic spacer Chemical group 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 230000010516 arginylation Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 208000025698 brain inflammatory disease Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 108010009297 diglycyl-histidine Proteins 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002710 external beam radiation therapy Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- GFSTXYOTEVLASN-UHFFFAOYSA-K gadoteric acid Chemical compound [Gd+3].OC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 GFSTXYOTEVLASN-UHFFFAOYSA-K 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 108010084264 glycyl-glycyl-cysteine Proteins 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000013152 interventional procedure Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000008384 membrane barrier Effects 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 210000005164 penile vein Anatomy 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229930182852 proteinogenic amino acid Natural products 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- ACTRVOBWPAIOHC-UHFFFAOYSA-N succimer Chemical compound OC(=O)C(S)C(S)C(O)=O ACTRVOBWPAIOHC-UHFFFAOYSA-N 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229910052713 technetium Inorganic materials 0.000 description 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- JLEXUIVKURIPFI-UHFFFAOYSA-N tris phosphate Chemical compound OP(O)(O)=O.OCC(N)(CO)CO JLEXUIVKURIPFI-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0368—Animal model for inflammation
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Definitions
- the present invention relates to the molecular imaging of inflammatory sites, in particular for determining whether a subject suffers or is at risk of having or developing an inflammatory condition and for monitoring the changes in the extent of an inflammatory condition after an anti-inflammatory treatment.
- Imaging of inflammation sites would be a useful tool for the diagnosis of an inflammation condition.
- the high level of glucose metabolism in inflammation has prompted to the use of 18 F-FDG (2-deoxy-2- 18 F-fluoro-D-glucose) PET.
- 18 F-FDG however suffers from poor specificity and its high physiologic uptake in the heart, lung and brain limits its use. More specific targets for imaging inflamed tissues are therefore needed.
- CD31 is a transmembrane glycoprotein receptor constitutively expressed by leukocytes, platelets and endothelial cells. It consists of a single chain molecule comprising six Ig-like extracellular domains, a short transmembrane segment and a cytoplasmic tail comprising two important tyrosine-based motifs (around Y663 and Y686) that act as Immunoreceptor Tyrosine-based Inhibitory Motifs (ITIMs).
- ITIMs Immunoreceptor Tyrosine-based Inhibitory Motifs
- CD31 Due to its homophilic and inhibitory functions, CD31 exerts a crucial role in the homeostasis of the circulation. In pro-inflammatory conditions, the homophilic portion of the receptor is lost due to a cleavage and activated cells express a truncated form of CD31.
- WO2010/000756 indeed discloses that CD31 is shed on activated/memory T lymphocytes between the 5th and the 6th extracellular Ig-like domains whereas WO2013/152919 discloses that activated platelets also express a CD31 that is truncated between the 6 th extracellular domain and the juxtamembrane sequence.
- Both types of shed extracellular sequences of CD31 are then released into the circulation, where they are present together with a soluble splice variant of CD31, produced by healthy endothelial cells.
- the remaining small CD31 ectodomain which remains anchored to the membrane after shedding is referred to as “CD31 shed ”.
- WO2010/000756 and WO2013/152919 discloses a method for diagnosing a thrombotic or an autoimmune disorder based on the detection of said soluble CD31 in a biological sample of an individual.
- WO2010/000741 discloses peptides corresponding to juxta-membrane amino acids of the ectodomain of CD31 that are able to rescue the physiological immunoregulatory function of CD31, by specifically targeting CD31 shed on activated leukocytes and platelets. Such peptides are useful for the treatment of thrombotic or autoimmune disorders.
- WO2013/190014 further discloses specific peptides of 8 amino acids, within the membrane juxta-proximal part of extracellular CD31, which hold useful for the treatment of thrombotic or inflammatory disorders and display physic-chemical properties that are more suitable for drug development.
- CD31 shed itself can be used as a molecular target for the diagnosis of an inflammatory condition, in particular by allowing the molecular imaging of inflammatory sites.
- CD31 shed was indeed surprisingly found to be present on activated cells in a quantity allowing to obtain a detectable signal when using a labeled CD31 shed ligand, whereas the noise signal corresponding to CD31 shed present on activated circulating cells and on other organs or cells not involved in inflammation was little, thereby leading to a good signal to noise ratio.
- the Inventors used peptide P8RI of sequence SEQ ID NO: 6 consisting of D-enantiomer amino acids coupled to HYNIC (6-Hydrazinopyridine-3-carboxylic acid) via a PEG spacer and radiolabeled with 99mTc. Said radiolabeled CD31 shed ligand was found stable both in vitro and in vivo and specific to CD31 shed , with very low binding to plasma proteins.
- labelled CD31 shed ligands in particular small peptides, able to specifically bind to CD31 shed are useful as a tracer for molecular imaging of inflammation.
- One object of the present invention is thus a labeled CD31 shed ligand comprising a CD31 shed ligand and at least one imaging label, preferably at least one radionuclide.
- Said CD31 shed ligand is preferably:
- the CD31 shed ligand of (v) preferably comprises at least one amino acid in the D-enantiomer form.
- the CD31 shed ligand is preferably selected in the group consisting of a peptide of sequence SEQ ID NO: 2, a peptide of sequence SEQ ID NO: 3, a peptide of sequence SEQ ID NO: 4, a peptide of sequence SEQ ID NO: 5, a peptide of sequence SEQ ID NO: 6 consisting of D-enantiomer amino acids, a peptide of sequence SEQ ID NO: 7 and a peptide of sequence SEQ ID NO: 8 consisting of D-enantiomer amino acids.
- a preferred CD31 shed ligand is a peptide of sequence SEQ ID NO: 5, or a peptide of sequence SEQ ID NO: 6 consisting of D-enantiomer amino acids.
- the radionuclide of the labeled CD31 shed ligand is preferably detectable by molecular imaging technique(s), such as Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), an hybrid of SPECT and/or PET, or their combinations.
- molecular imaging technique(s) such as Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), an hybrid of SPECT and/or PET, or their combinations.
- the radionuclide is technetium-99m (99mTc or 99m Tc), gallium-67 ( 67 Ga), gallium-68 ( 68 Ga), yttrium-90 ( 90 Y), indium-111 ( 111 In), rhenium-186 ( 186 Re), fluorine-18 ( 18 F), copper-64 ( 64 Cu) or thallium-201 ( 201 TI).
- a preferred labeled CD31 shed ligand comprises a peptide of sequence SEQ ID NO: 6 consisting of D-enantiomer amino acids as CD31 shed ligand and 99mTc as radionuclide.
- the CD31 shed ligand is coupled with HYNIC (6-Hydrazinopyridine-3-carboxylic acid), optionally via at least one spacer.
- Another object of the present invention relates to the labeled CD31 shed ligand as defined above for use as a molecular imaging agent for imaging of inflammatory sites, in particular for determining whether a subject suffers from an inflammatory condition, is at risk of having an inflammatory condition or is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment or for monitoring the efficacy of a treatment of an inflammatory condition.
- the present invention also relates to the use of the labeled CD31 shed ligand as defined above as a molecular imaging agent, in particular for imaging inflammation sites.
- Another object of the present invention relates to a method, preferably an in vitro method, for determining whether a subject suffers from an inflammatory condition, is at risk of having an inflammatory condition or is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment or for monitoring the efficacy of a treatment of an inflammatory condition, wherein said method comprises:
- Another object of the present invention relates to CD31 shed for use as a molecular imaging target for imaging of inflammatory sites, more particularly for determining whether a subject suffers from an inflammatory condition, is at risk of having an inflammatory condition, is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment or for monitoring the efficacy of a treatment of an inflammatory condition.
- the present invention also relates to the use of CD31 shed for use as a molecular imaging target, in particular for imaging inflammation sites.
- An inflammatory condition underlies a large number of diseases.
- the immune system is often involved with inflammatory conditions, as demonstrated in both allergic reactions and some myopathies, with many immune system disorders resulting in abnormal inflammation.
- inflammatory condition includes but is not limited to a chronic inflammatory condition, an immune disorder, an autoimmune disorder, an acute and chronic grant alloimmune conditions, an acute and chronic infectious-driven inflammatory condition, a non-immune disease with etiological origins in inflammatory processes or their combinations.
- the chronic inflammatory condition is for example inflammatory bowel disease, psoriasis, atopic dermatitis, cerebral amyloid angiopathy an/or vasculitis.
- An immune disorder is for example allergies and/or myopathy.
- the autoimmune disorder is for example rheumatoid arthritis (RA), multiple sclerosis (MS), inflammatory bowel disease (IBD), systemic lupus erythematodes (SLE), Graves' disease and/or diabetes mellitus.
- RA rheumatoid arthritis
- MS multiple sclerosis
- IBD inflammatory bowel disease
- SLE systemic lupus erythematodes
- Graves' disease and/or diabetes mellitus.
- Acute and chronic alloimmune conditions are for example allograft rejection or graft versus host disease (GVHD).
- GVHD graft versus host disease
- Acute and chronic infectious-driven inflammatory conditions include the formation of septic granulomas (abscess) and/or septic shock.
- the non-immune disease with etiological origins in inflammatory processes is for example cancer, thrombosis, ischaemic and/or ischemia-reperfusion organ damage (for example heart and/or brain infarction) arterial inflammatory condition (such as atherothrombosis, arterial dissection and/or unhealed/thromboses arterial aneurysm) and/or neurodegenerative disease.
- ischemia-reperfusion organ damage for example heart and/or brain infarction
- arterial inflammatory condition such as atherothrombosis, arterial dissection and/or unhealed/thromboses arterial aneurysm
- neurodegenerative disease for example cancer, thrombosis, ischaemic and/or ischemia-reperfusion organ damage (for example heart and/or brain infarction) arterial inflammatory condition (such as atherothrombosis, arterial dissection and/or unhealed/thromboses arterial aneurysm) and/or neurodegenerative disease.
- the inflammatory condition is for example selected from the group consisting of rheumatoid arthritis, multiple sclerosis, allergies, myopathy, inflammatory bowel disease, psoriasis, atopic dermatitis, cerebral amyloid angiopathy, vasculitis, systemic lupus erythematosus, Graves' disease, diabetes mellitus, acute or chronic graft rejection, cancer, thrombosis, atherothrombosis, ischaemic heart and/or brain infarction, and/or neurodegenerative disease.
- a “subject” in the context of the present invention is a human being or a non-human mammal.
- Said human being may be of any sex, for example male or female and of any age, for example an infant, child, adolescent, adult, elderly people.
- a non-human mammal is preferably a mouse, rat, cat, dog, rabbit, hamster, swine, sheep, horse or primate.
- the subject may suffer from an inflammatory condition, be suspected to suffer from an inflammatory condition, be at risk of having an inflammatory condition or be at risk of recurrence of an inflammatory condition.
- “Risk” in the context of the present invention relates to the probability that an event will occur over a specific time period, for example the conversion to an inflammatory condition.
- imaging of inflammation sites and “imaging of inflammation” are herein synonymous.
- Imaging of inflammation sites allows to localize the inflamed tissues and/or inflamed organs in the body of a subject.
- imaging of inflammation sites allows diagnosing an inflammation condition, confirming an inflammation condition, localizing the inflamed tissues or organs, monitoring the response to a treatment, for example to an anti-inflammatory treatment, monitoring the inflammatory side-effects of a treatment, predicting the risk of developing an inflammatory condition and/or determining the risk of recurrence of an inflammatory condition after an anti-inflammatory treatment.
- Imaging of inflammation sites may thus be used for determining whether a subject suffers from an inflammatory condition, is at risk of having an inflammatory condition, is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment or for monitoring the efficacy of a treatment of an inflammatory condition.
- a molecular imaging target and/or a molecular imaging agent are needed to carry out imaging of inflammation.
- molecular imaging target refers to a compound that can be detected by using molecular imaging techniques.
- molecular imaging agent refers to a compound that can be used to detect specific biological elements, in particular a molecular imaging target, by using molecular imaging techniques.
- the molecular imaging agent is preferably an agent coupled to an imaging label, covalently or non-covalently.
- the molecular imaging agent is used to detect CD31 shed in vivo or in vitro, for example in a blood sample of a subject.
- CD31 shed for Use as a Molecular Imaging Target
- the present invention thus relates to CD31 shed for use as a molecular imaging target for imaging of inflammation sites.
- the present invention also relates to the use of CD31 shed as a molecular imaging target for imaging of inflammation sites.
- the present invention particularly relates to CD31 shed for use as a molecular imaging target in a method for imaging inflammation sites, particularly in vivo.
- CD31 shed refers to the remaining small CD31 ectodomain which remains anchored to the membrane of endothelial cells, platelets or leukocytes, after shedding of the CD31 transmembrane glycoprotein receptor.
- CD31 shed on the surface of activated endothelial cells, platelets and leukocytes lacks at least the 1 st to 5 th extracellular Ig-like domains of CD31.
- CD31 shed on the surface of activated platelets and activated endothelial cells lacks the 1 st to 5 th extracellular Ig-like domains of CD31 and at least one part of the 6th extracellular Ig-like domain.
- CD31 shed on the surface of activated leukocytes lacks the 1 st to 5 th extracellular Ig-like domains, but comprises the 6th extracellular Ig-like domain.
- the present invention also relates to CD31 shed for use as defined above, in a method, preferably an in vivo method, for determining whether a subject suffers from an inflammatory condition, is at risk of having an inflammatory condition, is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment or for monitoring the efficacy of a treatment of an inflammatory condition.
- the present invention also relates to CD31 shed for use for determining whether a subject suffers from an inflammatory condition, is at risk of having an inflammatory condition, is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment or for monitoring the efficacy of a treatment of an inflammatory condition, in particular in vivo.
- inflammation condition and “imaging of inflammation sites” are as defined above.
- CD31 shed ligand refers to any compound that is able to specifically bind with CD31 shed .
- the specific binding of a compound to CD31 shed present on a cell surface may be assessed by any method well-known by the skilled person.
- the specific binding may be measured by plasmon surface resonance, flow cytometry or beta-imager.
- the binding of a compound to be tested to CD31 shed present on a cell surface is assessed as follows: the compound to be tested, or an irrelevant analogue as negative control, is bound to a fluorescent probe (e.g. fluoresceine).
- a fluorescent probe e.g. fluoresceine
- the compound is incubated at consecutive dilutions (for example 1, 10, 100 ⁇ mol) with CD31+ cells (for example from a cell line, such as Jurkat T cells, or primary cells, such as peripheral blood T cells), at a density of 10 6 cells/ml in a saline buffer comprising Ca++ and Mg++ (HBSS, culture medium). Parallel conditions are incubated in the presence of a cell activator (e.g.
- TCR crosslinking such as 1 ⁇ g/ml anti-CD3e antibodies+20 ⁇ g/ml secondary F(ab′)2 fragment if the cells are T lymphocytes).
- the reaction is stopped after 5 or 20 minutes by repeated washing steps with cold buffer. Cells are fixed with paraformaldehyde and washed again. Binding of the compound to be tested on individual cells is detected by the relative fluorescent signal using a flow cytometer. A greater signal for the specific compound as compared to the control and in the conditions comprising the cell activator as compared to resting cells indicates appropriate binding to CD31 shed .
- the compound to be tested is tested for its binding to activated endothelial cells (for example primary cells from human blood vessels of immortalized cell lines).
- activated endothelial cells for example primary cells from human blood vessels of immortalized cell lines.
- the cells are cultured on collagen type I thin layer to confluence.
- the cells are incubated with 20 ng/ml Human recombinant TNFa for 30 minutes in culture medium.
- the reaction is stopped by rinsing the cells with cold saline buffer and the cells are fixed (for instance with a Zinc-fixative solution for 10 minutes at room temperature).
- activated endothelial cells are labeled by the compound to be tested, or an irrelevant analogue as negative control, is bound to a fluorescent probe (e.g. fluoresceine) and counterstained by a plasma membrane dye (e g Cell MaskTM) and a nuclear staining (eg Hoechst 33342). Binding of the compound to be tested on individual cells is detected by the relative fluorescent signal using a fluorescence microscope. A greater signal for the specific compound as compared to the control and in the conditions comprising the cell activator as compared to resting cells indicates appropriate binding to CD31 shed .
- a fluorescent probe e.g. fluoresceine
- a plasma membrane dye e g Cell MaskTM
- a nuclear staining eg Hoechst 33342
- the CD31 shed ligand may be a peptide, a peptidomimetic, a chemical compound, an antibody or an aptamer.
- antibody is thus used to refer to any antibody-like molecule that has an antigen binding region, and this term includes antibody fragments that comprise an antigen binding domain such as Fab′, Fab, F(ab′)2, single domain antibodies (DABs or VHH), TandAbs dimer, Fv, scFv (single chain Fv), dsFv, ds-scFv, Fd, linear antibodies, minibodies, diabodies, bispecific antibody fragments, bibody, tribody (scFv-Fab fusions, bispecific or trispecific, respectively); sc-diabody; kappa(lamda) bodies (scFv-CL fusions); DVD-Ig (dual variable domain antibody, bispecific format); SIP (small immunoprotein, a kind of minibody); SMIP (“small modular immunopharmaceutical” scFv-Fc dimer; DART (ds-stabilized diabody “Dual Affinity ReTargeting”
- the antibody is a monoclonal antibody.
- the antibody is non-internalizing.
- non-internalizing antibody refers to an antibody, respectively, that has the property of to bind to a target antigen present on a cell surface, and that, when bound to its target antigen, does not enter the cell and become degraded in the lysosome.
- the heterologous polypeptide is a light immunoglobulin chain.
- the heterologous polypeptide is a heavy immunoglobulin chain.
- the heterologous polypeptide is a heavy single heavy chain variable domain of antibodies of the type that can be found in Camelid mammals which are naturally devoid of light chains.
- the antibody is a single domain antibody.
- single domain antibody has its general meaning in the art and refers to the single heavy chain variable domain of antibodies of the type that can be found in Camelid mammals which are naturally devoid of light chains. Such single domain antibody are also called VHH or “nanobody®”.
- VHH single domain antibody
- single domain antibody are also called VHH or “nanobody®”.
- (single) domain antibodies reference is also made to the prior art cited above, as well as to EP 0 368 684, Ward et al. (Nature 1989 Oct 12; 341 (6242): 544-6), Holt et al., Trends Biotechnol., 2003, 21(11):484-490; and WO 06/030220, WO 06/003388.
- the amino acid sequence and structure of a single domain antibody can be considered to be comprised of four framework regions or “FRs” which are referred to in the art and herein as “Framework region 1” or “FRI”; as “Framework region 2” or “FR2”; as “Framework region 3” or “FR3”; and as “Framework region 4” or “FR4” respectively; which framework regions are interrupted by three complementary determining regions or “CDRs”, which are referred to in the art as “Complementarity Determining Region for “CDRI”; as “Complementarity Determining Region 1” or “CDR2” and as “Complementarity Determining Region 2” or “CDR3” and as “Complementarity Determining Region 2”, respectively.
- the single domain antibody can be defined as an amino acid sequence with the general structure: FRI—CDRI—FR2—CDR2—FR3—CDR3—FR4 in which FRI to FR4 refer to framework regions 1 to 4 respectively, and in which CDRI to CDR3 refer to the complementarity determining regions 1 to 3.
- the amino acid residues of the single domain antibody are numbered according to the general numbering for VH domains given by the International ImMunoGeneTics information system aminoacid numbering (http://imgt.cines.fr/).
- the antibody is a single chain variable fragment.
- the term “single chain variable fragment” or “scFv fragment” refers to a single folded polypeptide comprising the VH and VL domains of an antibody linked through a linker molecule.
- the VH and VL domains can be either in the VH—linker—VL or VL—linker—VH order.
- a scFv fragment may contain a tag molecule linked to the scFv via a spacer.
- a scFv fragment thus comprises the VH and VL domains implicated into antigen recognizing but not the immunogenic constant domains of corresponding antibody.
- the CD31 shed ligand is a peptide.
- the peptide is preferably a peptide as disclosed in WO2010/000741 or WO2013/190014.
- the CD31 shed ligand is a synthetic peptide.
- a “synthetic peptide” it is intended that the peptide is not present within a living organism, e.g. within human body.
- the synthetic peptide is preferably purified.
- the synthetic peptide may be part of a composition or a kit.
- the peptide may be selected in the group consisting of:
- a “fragment” refers herein to a sequence of consecutive amino acids.
- a fragment may be a fragment of 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids.
- sequence SEQ ID NO: 12 The sequence defined by amino acids 579 to 601 of sequence SEQ ID NO: 1 is sequence SEQ ID NO: 12.
- the peptide may consist of a fragment of 3 to 15 amino acids of sequence SEQ ID NO: 12.
- the peptide may also consist of a fragment of 3 to 15 amino acids of a sequence corresponding to sequence SEQ ID NO: 12 in a non-human mammalian CD31.
- Non-limiting examples of non-human mammalian CD31 are the murine CD31 of sequence SEQ ID NO: 9, the bovine CD31 of sequence SEQ ID NO: 10 and the pig CD31 of sequence SEQ ID NO: 11.
- sequence SEQ ID NO: 12 The person skilled in the art can easily identify a sequence corresponding to the amino acids 579 to 601 of sequence SEQ ID NO: 1, i.e. to sequence SEQ ID NO: 12, in a non-human mammalian CD31 protein, for example by performing a sequence alignment between sequence SEQ ID NO: 1 and the sequence of said non-human mammalian CD31 protein, for example with one of sequences SEQ ID NO: 9, SEQ ID NO: 10 and SEQ ID NO: 11.
- sequence alignment and determination of sequence identity are well known in the art, for example using publicly available computer software such as BioPerl, BLAST, BLAST-2, CS-BLAST, FASTA, ALIGN, ALIGN-2, LALIGN, Jaligner, matcher or Megalign (DNASTAR) software and alignment algorithms such as the Needleman-Wunsch and Smith-Waterman algorithms.
- publicly available computer software such as BioPerl, BLAST, BLAST-2, CS-BLAST, FASTA, ALIGN, ALIGN-2, LALIGN, Jaligner, matcher or Megalign (DNASTAR) software and alignment algorithms such as the Needleman-Wunsch and Smith-Waterman algorithms.
- the sequence of the CD31 peptide according to the invention is preferably derived from the sequence of human CD31 or murine CD31.
- the peptide may also be a peptide of 3 to 15 amino acids consisting of a sequence at least 70%, at least 75%, at least 80%, at least 85% or at least 90% identical to the sequence of peptide (i), i.e. to the sequence of a fragment of 3 to 15 amino acids of the sequence defined by amino acids 579 to 601 of sequence SEQ ID NO: 1.
- a peptide sequence at least 70% identical to a given sequence of 4 to 6 amino acids differs from said given sequence of at most one amino acid.
- a peptide sequence at least 70% identical to a given sequence of 7 to 9 amino acids differs from said given sequence of at most two amino acids.
- a peptide sequence at least 70% identical to a given sequence of 10 to 13 amino acids differs from said given sequence of at most three amino acids.
- a peptide sequence at least 70% identical to a given sequence of 14 or 15 amino acids differs from said given sequence of at most four amino acids.
- a sequence at least x % identical to a reference sequence it is intended that the amino acid sequence of the subject peptide is identical to the reference sequence or differ from the reference sequence by up to 100-x amino acid alterations per each 100 amino acids of the reference sequence.
- up to 100-x % of the amino acid residues in the subject sequence may be inserted, deleted or substituted with another amino acid.
- comparison matrix BLOSUM62
- gap open penalty 10
- gap extend penalty 0.5
- end gap penalty false
- end gap open penalty 10
- end gap extend penalty 0.5
- Peptides consisting of an amino acid sequence “at least 70%, 75%, 80%, 85%, or 90% identical” to a reference sequence may comprise mutations, such as deletions, insertions and/or substitutions compared to the reference sequence.
- substitutions preferably corresponds to a conservative substitution as indicated in the Table 1 below.
- the peptide consisting of an amino acid sequence at least 70%, 75%, 80%, 85% or 90% identical to a reference sequence only differs from the reference sequence by conservative substitutions.
- the peptide consisting of an amino acid sequence at least 70%, 75%, 80%, 85% or 90% identical to a reference sequence corresponds to a naturally-occurring allelic variant of the reference sequence.
- the peptide consisting of an amino acid sequence at least 70%, 75%, 80%, 85%or 90% identical to a reference sequence corresponds to a homologous sequence derived from another non-human mammalian species than the reference sequence.
- the peptide consisting of an amino acid sequence at least 70%, 75%, 80%, 85% or 90% identical to a reference sequence differs from the reference sequence by conservative substitutions and/or corresponds to a homologous sequence derived from another non-human mammalian species than the reference sequence.
- a peptide consisting of a retro-inverso sequence of peptide (i), (ii) or (iii) it is herein meant a peptide that differs from the peptide (i), (ii) or (iii) in that its amino acids are in the reverse order by comparison to the sequence of peptide (i), (ii) or (iii), respectively, and consist of D-amino acids instead of the naturally-occurring L-amino acids.
- D-enantiomers of amino acids are referred to by the same letter as their corresponding L-enantiomer (also called L-amino acid), but in lower case.
- L-enantiomer of arginine is referred to as ‘R’
- r D-enantiomer
- the peptide is soluble in an organic or nonorganic solvent.
- the peptide is soluble in water. More particularly, the peptide is preferably soluble in water and/or in aqueous buffer such as trifluoroacetate (for example in a 0.1% trifluoroacetate solution), NaCl 9 g/L, PBS, Tris or Tris-phosphate.
- aqueous buffer such as trifluoroacetate (for example in a 0.1% trifluoroacetate solution), NaCl 9 g/L, PBS, Tris or Tris-phosphate.
- the solubility in water and aqueous buffers is particularly advantageous on the pharmacological point of view. Thanks to such solubility, the peptide may be dissolved in an aqueous solution, for example at a concentration equal to, at least of or at most of 1 micromolar, 10 micromolar, 50 micromolar, 100 micromolar, 500 micromolar, 1 mM, 50 mM or 100 mM.
- a CD31 shed ligand of the invention that is readily soluble in water may be obtained by the presence of at least one charged amino acid (preferably arginine (R) and/or lysine (K)), wherein said charged amino acid is not comprised between two hydrophobic residues.
- at least one charged amino acid preferably arginine (R) and/or lysine (K)
- said charged amino acid is not comprised between two hydrophobic residues.
- the CD31 shed ligand according to the invention comprises at least one charged amino acid, preferably arginine and/or lysine, wherein said charged amino acid is not comprised between two hydrophobic residues.
- said charged amino acid is located either at the N- or C-terminal end of the sequence.
- sequence of a preferred CD31 shed ligand according to the invention begins with the motif RV (for example instead of VRV).
- the peptide is resistant to peptidase, in particular to eukaryote peptidase.
- resistant to peptidase it is herein meant that the CD31 shed ligand remains undigested, as determined by reverse phase—high-performance liquid chromatography (RP-HPLC) and mass spectroscopy (MS), upon incubation at 37° C. with mammalian serum or injection in a living laboratory animal. Laboratory tests aimed at evaluating serum stability of the peptides are well standardized (see for example Jenssen and Aspmo, 2008, Methods Mol Biol 494, 177-186).
- Highly peptidase-resistant peptides are those that remains undigested for up to 70% of their original mass and/or displaying a half life longer than 240 minutes in the presence of proteolytic enzymes (see for example Kumarasinghe and Hruby, 2015, In Peptide Chemistry and Drug Design, B. M. Dunn, ed. (Hoboken, N.J.: Wiley), pp. 247-266).
- the CD31 shed ligand is preferably resistant to peptidases present in blood, such as soluble peptidases or peptidases present on cell surface.
- the CD31 shed ligand may also comprise at least one or at least one further chemical modification, preferably to improve its stability and/or bioavailability.
- the CD31 shed ligand may comprise at least one artificial amino acid, said artificial amino acid being preferably selected from the group consisting of a D-enantiomer amino acid, a beta-methyl amino acid, a alpha-substituted alpha-amino acid and an amino acid analog.
- beta-methyl amino acid it is herein meant a derivative of the amino acid alanine with an aminomethyl group on the side chain. This non-proteinogenic amino acid is classified as a polar base.
- alpha-substituted alpha-amino acid it is herein meant that the group on the alpha carbon of an L-amino acid (NH2) has been changed to another, non proteinaceous group, such as a methyl-, aryl- or acyl- group.
- amino acid analog any other artificial analog of a natural amino acid.
- the CD31 shed ligand may thus comprise at least one amino acid in the D-enantiomer form.
- 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 of the amino acids of the CD31 shed ligand defined above may be in the D-enantiomer form.
- the CD31 shed ligand consists of D-amino acids.
- the CD31 shed ligand may also comprise an inverted sequence, namely an inversion of the amino acid chain (from the C-terminal end to the N-terminal end).
- the entire amino acid sequence of the peptide may be inverted, or a portion of the amino acid sequence may be inverted.
- a consecutive sequence of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids may be inverted.
- Reference herein to ‘inverted’ amino acids refers to inversion of the sequence of consecutive amino acids in the sequence.
- the CD31 shed ligand includes amino acids modified either by natural processes, such as post-translational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modification(s) can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini, it will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching.
- Cyclic, branched and branched cyclic polypeptides may result from natural post-translational processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, araidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidyl inositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutarnate, formylation, gamma-carboxylation, glycosylation, GP 6 ′I anchor formation, hydroxylation, iodination, mefhylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoyiation
- the CD31 shed ligand is selected in the group consisting of:
- Such peptide has, for example, a sequence selected from the group consisting of: SSTLAVRVFLAPWKK (SEQ ID NO: 13, amino acids 576 to 590 of SEQ ID NO: 9), STLAVRVFLAPWKK (SEQ ID NO: 14, amino acids 577 to 590 of SEQ ID NO: 9), TLAVRVFLAPWKK (SEQ ID NO: 15, amino acids 578 to 590 of SEQ ID NO: 9), LAVRVFLAPWKK (SEQ ID NO: 16, amino acids 579 to 590 of SEQ ID NO: 9), AVRVFLAPWKK (SEQ ID NO: 17, amino acids 580 to 590 of SEQ ID NO: 9), VRVFLAPWKK (SEQ ID NO: 3, amino acids 581 to 590 of SEQ ID NO: 9), RVFLAPWKK (SEQ ID NO: 18, amino acids 582 to 590 of SEQ ID NO: 9), VFLAPWKK (SEQ ID NO: 19, amino acids 583 to 590 of SEQ ID NO: 9), FLAPW
- the CD31 shed ligand is selected in the group consisting of:
- the CD31 shed ligand is an 8 amino-acid fragment comprising inversions and/or at least one unnatural amino acid, such as at least one D-amino acids.
- Such peptides indeed retain the activity of the original peptide or even demonstrate improved activity.
- Incorporation of unnatural amino acids in peptides intended for therapeutic use is of utility in increasing the stability of the peptide, in particular in vivo stability.
- the CD31 shed ligand is selected in the group consisting of a peptide of sequence SEQ ID NO: 2, a peptide of sequence SEQ ID NO: 3, a peptide of sequence SEQ ID NO: 4, a peptide of sequence SEQ ID NO: 5, a peptide of sequence SEQ ID NO: 6 consisting of D-enantiomer amino acids, a peptide of sequence SEQ ID NO: 7 and a peptide of sequence SEQ ID NO: 8 consisting of D-enantiomer amino acids.
- a more preferred CD31 shed ligand is a peptide of sequence SEQ ID NO: 5 or a peptide of sequence SEQ ID NO: 6 consisting of D-enantiomer amino acids.
- the CD31 shed ligand may additionally comprise at least one chelating agent.
- a chelating agent is a molecule covalently bound to the ligand, which allows complexing radiometal(s).
- chelating agents could be: 6-Hydrazinopyridine-3-carboxylic acid (HYNIC), chelating peptide such as Gly-Gly-Cys or His-based sequence (Francesconi 2004, Waibel 1999, Ali 2011), MAG3 en N-ter (Okarvi 2012, 2004), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetracetic acid (DOTA), diethylene triamine penta-acetic acid (DTPA), 1,4,7-tris(carboxymethylaza)cyclododecane-10-azaacetylamide (DO3A), nitrilotriacetic acid (NTA), D-penicillamine, 2,3-dimercaptosuccinic acid,2,3-dimercapto-1-propanesulfonic acid, 2,3-dimercaptopropanol (BAL), triethylenetetramine, ammonium tetrathiomolybdate anion,
- the CD31 shed ligand may be linked to the chelating agent directly (for example the chelating agent being attached to a lateral amino acid long chain) or indirectly, for example via at least one spacer.
- a preferred chelating agent is 6-Hydrazinopyridine-3-carboxylic acid (HYNIC).
- the peptide of the CD31 shed ligand may be linked to HYNIC directly (for example HYNIC being attached to a lateral amino acid long chain) or indirectly, for example via at least one spacer.
- the spacer for example comprises or consists of at least one PEG (polyethylene glycol), for example one, two or at least three PEG, more preferably three PEG and/or at least one aliphatic spacer.
- PEG polyethylene glycol
- a preferred CD31 shed ligand is a compound of the following formula:
- This compound is also called HYNIC-P8RI in the following.
- the CD31 shed ligand may be prepared by any well-known procedure in the art, such as chemical synthesis, for example solid phase synthesis or liquid phase synthesis, or genetic engineering.
- chemical synthesis for example solid phase synthesis or liquid phase synthesis, or genetic engineering.
- solid phase synthesis for example, the amino acid corresponding to the C-terminus of the peptide to be synthesized is bound to a support which is insoluble in organic solvents, and by alternate repetition of reactions, one wherein amino acids with their amino groups and side chain functional groups protected with appropriate protective groups are condensed one by one in order from the C-terminus to the N-terminus, and one where the amino acids bound to the resin or the protective group of the amino groups of the peptides are released, the peptide chain is thus extended in this manner.
- Such peptide cutting reaction may be carried with hydrogen fluoride or tri-fluoromethane sulfonic acid for the Boc method, and with TFA for the Fmoc method.
- Solid phase synthesis methods are largely classified by the tBoc method and the Fmoc method, depending on the type of protective group used.
- protective groups include tBoe (t-butoxycarbonyl), CI-Z (2-chlorobenzyloxycarbonyl), Br-Z (2-bromobenzyloyycarbonyl), Bzl (benzyl), Fmoc (9-fluorenylmcthoxycarbonyl), Mbh (4,4′-dimethoxydibenzhydryl), Mtr (4-methoxy-2,3,6-trimethylbenzenesulphonyl), Trt (trityl), Tos (tosyl), Z (benzyloxycarbonyl) and Clz-Bzl (2,6-dichlorobenzyl) for the amino groups; NO2 (nitro) and Pmc (2,2, 5,7, 8-pentamethylchromane-6-sulphonyl) for the guanidino groups); and tBu (
- the CD31 shed ligand may be synthesized using recombinant techniques.
- the method of producing the CD31 shed ligand may optionally comprise the steps of purifying said CD31 shed ligand, chemically modifying said CD31 shed ligand, and/or formulating said CD31 shed ligand into a pharmaceutical composition.
- the CD31 shed ligand is a peptidomimetic of a peptide as defined above, i.e. a compound that mimics said peptide.
- a «peptidomimetic» is a compound consisting of or essentially consisting of non-peptidic structural elements that mimics a given peptide, thereby conferring to said compound a biological activity equal to or similar to said peptide.
- the peptidomimetic is preferably soluble in an organic or nonorganic solvent.
- the peptidomimetic is preferably soluble in water.
- the labeled CD31 shed ligand according to the invention comprises at least one imaging label.
- Said imaging label may be a radionucleide or a contrastophor.
- contrast agent refers to a contrast agent, for example comprising a chelating agent.
- chelating agent that may be used in a contrastophor are given below in the section “CD31 shed ligand”.
- Non-limitative examples of contrastophor are Gd-DTPA (complex of gadolinium and DTPA) or Gd-DOTA (complex of gadolinium and DOTA).
- a contrastophor is preferably used in MRI (also called thereafter “IRM” or “Magnetic Resonance Imaging”).
- radioactive nuclide as used herein has the same meaning as radioactive nuclide, radioisotope or radioactive isotope.
- the radionuclide is preferably detectable by nuclear medicine molecular imaging technique(s), such as, Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), an hybrid of SPECT and/or PET or their combinations.
- nuclear medicine molecular imaging technique(s) such as, Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), an hybrid of SPECT and/or PET or their combinations.
- Single Photon Emission Computed Tomography herein includes planar scintigraphy (PS).
- An hybrid of SPECT and/or PET is for example SPECT/CT, PET/CT, PET/IRM or SPECT/IRM.
- SPECT and PET acquire information on the concentration (or uptake) of radionuclides introduced into a subject's body.
- PET generates images by detecting pairs of gamma rays emitted indirectly by a positron-emitting radionuclide.
- a PET analysis results in a series of thin slice images of the body over the region of interest (e.g., brain, breast, liver, . . . ). These thin slice images can be assembled into a three dimensional representation of the examined area.
- SPECT is similar to PET, but the radioactive substances used in SPECT have longer decay times than those used in PET and emit single instead of double gamma rays.
- SPECT images exhibit less sensitivity and are less detailed than PET images, the SPECT technique is much less expensive than PET and offers the advantage of not requiring the proximity of a particle accelerator.
- Actual clinical PET presents higher sensitivity and better spatial resolution than SPECT, and presents the advantage of an accurate attenuation correction due to the high energy of photons; so PET provides more accurate quantitative data than SPECT.
- Planar scintigraphy is similar to SPECT in that it uses the same radionuclides. However, PS only generates 2D-information.
- SPECT produces computer-generated images of local radiotracer uptake
- CT produces 3-D anatomic images of X ray density of the human body.
- Combined SPECT/CT imaging provides sequentially functional information from SPECT and the anatomic information from CT, obtained during a single examination.
- CT data are also used for rapid and optimal attenuation correction of the single photon emission data.
- SPECT/CT improves sensitivity and specificity, but can also aid in achieving accurate dosimetric estimates as well as in guiding interventional procedures or in better defining the target volume for external beam radiation therapy.
- Gamma camera imaging with single photon emitting radiotracers represents the majority of procedures.
- the radionuclide is detectable by SPECT or an hybrid SPECT/CT.
- the radionuclide may be selected in the group consisting of technetium-99m ( 99m Tc), gallium-67 ( 67 Ga), gallium-68 ( 68 Ga) yttrium-90 ( 90 Y), indium-111 ( 111 In), rhenium-186 ( 186 RE), flourine-18 ( 18 F), copper-64 ( 64 Cu) or thallium-201 ( 201 TI).
- a preferred radionuclide is technetium-99m (99mTc).
- the present invention thus particularly relates to a labeled CD31 shed ligand comprising a CD31 shed ligand and at least one imaging label.
- the CD31 shed ligand and the imaging label are as defined above in the sections of the same name.
- the radiochemical specific activity of labeled CD31 shed ligand is preferably greater than 70 GBq/pmol, more preferably greater than 80 GBq/pmol, more preferably greater than 90 GBq/pmol, for example greater than 100 GBq/pmol.
- the labeled CD31 shed ligand is preferably stable.
- the stability of the labeled CD31 shed ligand may be assessed in vitro and/or in vivo by any method well known by the skilled person, for example by determining radiochemical purity (RCP).
- RCP radiochemical purity
- the radiochemical purity (RCP) may be assessed by high performance liquid chromatography (HPLC) and/or instant thin layer chromatography (ITLC), preferably using both methods.
- HPLC high performance liquid chromatography
- ITLC instant thin layer chromatography
- the in vitro stability may be assessed after incubation of the labeled CD31 shed ligand in vitro in plasma, preferably in human plasma at 37° C., for example for at least 1 hour, at least 2 hours, at least 3 hours or at least 4 hours.
- the in vivo stability may be assessed in a sample of human or non-human mammal urine, for example of rat urine, after administration of the labeled CD31 shed ligand in said human or non-human mammal.
- the in vitro and/or in vivo RCP of the labeled CD31 shed ligand is preferably greater than 80%, preferably greater than 85%, for example greater than 89%.
- the biodistribution and specific uptake of the labeled CD31 shed ligand by activated platelets, endothelial cells and leukocytes may be assessed in an inflammation model, for example in a rat model of heart inflammation, brain inflammation or vascular inflammation, such as the experimental abdominal aorta aneurysm (AAA) induced by local infusion of elastase and followed by intravenous injection of a periodontal bacterium present in human AAA and known to induce AAA inflammation.
- AAA abdominal aorta aneurysm
- sequential whole-body acquisitions for example every 10 minutes for the first hour
- are performed for example using a hybrid SPECT/CT camera (NanoSPECT/CT, Bioscan Inc.).
- the binding of the labeled CD31 shed ligand to plasma proteins is preferably low, for example lower than 10%, more preferably lower than 5% after 4 hours of incubation in human plasma at 37° C.
- the low binding to plasma proteins may be assessed by any method well known by the skilled person, such as size exclusion chromatography, for example after incubation of the labeled CD31 shed ligand in vitro in plasma, preferably in human plasma, at 37° C., for example for at least 1 hour, at least 2 hours, at least 3 hours or at least 4 hours.
- the CD31 shed ligand and the imaging label may be linked covalently or non-covalently.
- the CD31 shed ligand and the imaging label are preferably linked non-covalently.
- the CD31 shed ligand comprises a chelating agent
- the CD31 shed ligand is preferably linked to the imaging label via said chelating agent, and preferably non covalently.
- the labeled CD31 shed ligand is preferably a radiolabeled CD31 shed ligand.
- a preferred labeled CD31 shed ligand thus comprises a CD31 shed ligand and at least one radionuclide.
- the labeled CD31 shed ligand comprises a peptide of sequence SEQ ID NO: 6 consisting of D-enantiomer amino acids as CD31 shed ligand and 99 mTc as a radionuclide.
- the labeled CD31 shed ligand may additionally comprise at least one co-ligand, i.e. one or more ligands coupled to the CD31 shed ligand,
- the co-ligand(s) is/are preferably used to stabilize the imaging label binding to the CD31 shed ligand.
- the co-ligand may be tricine, EDDA (ethylendiaminediacetic acid) (EDDA), aminocarboxylate, phosphine or pyridine.
- EDDA ethylendiaminediacetic acid
- aminocarboxylate aminocarboxylate
- phosphine pyridine.
- the labeled CD31 shed ligand comprises both tricine and EDDA as co-ligands, for example when the radionuclide is 99mTc.
- the labeled CD31 shed ligand comprises or consists of a complex comprising said co-ligand(s), said CD31 shed ligand and said radionuclide.
- the CD31 shed ligand is the peptide of sequence SEQ ID NO: 6 consisting of D-enantiomer amino acids coupled with HYNIC via a spacer as defined above.
- a preferred labeled CD31 shed ligand referred to as 99mTc-HYNIC-P8RI, comprises:
- HYNIC forms a 99mTc-N bond between technetium and the hydrazine moiety of HYNIC.
- the labeled CD31 shed ligand can be prepared by conventional methods perfectly known by a man skilled in the art.
- the labeled CD31 shed ligand may be used per se or as a pharmaceutical composition as defined below.
- the present invention also relates to the use of a labeled CD31 shed ligand as defined above as a molecular imaging agent for imaging inflammation sites.
- the present invention thus also relates to a labeled CD31 shed ligand as defined above for use as a molecular imaging agent for imaging of inflammatory sites.
- the present invention particularly relates to a labeled CD31 shed ligand as defined above for use as a molecular imaging agent in an in vivo method of detecting, more particularly imaging, inflammatory sites.
- the present invention relates to a labeled CD31 shed ligand for use as defined above, in a method, preferably an in vivo method, for determining whether a subject suffers from an inflammatory condition, is at risk of having an inflammatory condition or is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment or for monitoring the efficacy of a treatment of an inflammatory condition.
- the invention also relates to a labeled CD31 shed ligand for use as defined above, wherein the presence, localization and/or amount of CD31 shed is determined.
- the labeled CD31 shed ligand indeed binds to CD31 shed .
- the presence, localization and/or amount of CD31 shed is determined by the presence, localization and/or amount of the labeled CD31 shed ligand, i.e. of the signal detected corresponding to the imaging label of said labeled CD31 shed ligand.
- the presence, localization and/or amount of the labeled CD31 shed ligand may be determined by planar scintigraphy (PS), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), an hybrid SPECT/CT or their combinations.
- PS planar scintigraphy
- PET Positron Emission Tomography
- SPECT Single Photon Emission Computed Tomography
- hybrid SPECT/CT or their combinations.
- the labeled CD31 shed ligand is preferably used or administered intravenously.
- the labeled CD31 shed ligand is preferably used or administered in an amount sufficient to obtain a detectable signal, in particular one injected intravenously.
- the signal corresponding to the imaging label of the labeled CD31 shed ligand is preferably detected immediately after the administration of the labeled CD31 shed ligand.
- the signal may be detected in the entire body of the subject or in only one part of the subject (particularly in only one part of the body of the subject).
- the present invention thus particularly relates to a labeled CD31 shed ligand as defined above for use in a method for detecting, more particularly imaging, inflammation sites, wherein said method comprises:
- the present invention thus particularly relates to a labeled CD31 shed ligand as defined above for use in a method for determining whether a subject suffers from an inflammatory condition, is at risk of having an inflammatory condition or is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment or for monitoring the efficacy of a treatment of an inflammatory condition, wherein said method comprises:
- the molecular imaging agent of the invention represents a powerful tool for diagnosing or assessing an inflammatory condition associated with CD31 shed .
- the subject to be diagnosed is suspected to suffer or be likely to suffer from an inflammatory condition or suffers from an inflammatory condition.
- the method can indeed be performed to confirm that the subject suffers from an inflammatory condition and/or to specify the kind of inflammatory condition.
- the presence, localization and/or amount of CD31 shed may indicate that the subject suffers from an inflammatory condition.
- the localization of CD31 shed may further indicate the kind of inflammatory condition.
- the amount of CD31 shed may further indicate the severity of the inflammation condition.
- the presence, localization and/or amount of CD31 shed may be compared to a reference value or a control biological image.
- a reference value or the control biological sample corresponds to a healthy subject, in particular a subject that does not suffer from an inflammatory condition or a panel of healthy subjects
- a presence, localization and/or amount of CD31 shed detected in the biological sample that is greater than those of reference value or of the control image indicates that the subject suffers or, is at risk of having an inflammatory condition.
- the methods and uses according to the invention can also be used to follow the risk of recurrence of an inflammatory condition after an anti-inflammatory treatment.
- they can be used to monitor the subject after an anti-inflammatory treatment. For example, this can be achieved by repeating the method at least one time, preferably two times after the end of said treatment, in order to determine the presence, localization and/or amount of CD31 shed .
- An increased presence, localization and/or amount of CD31 shed may indicate a high risk of recurrence of an inflammatory condition after an anti-inflammatory treatment.
- a stable or a decreased presence, localization and/or amount of CD31 shed may indicate a low risk of recurrence of an inflammatory condition after an anti-inflammatory treatment.
- an image of a biological sample and/or of the subject or at least one part of the subject is generated at the end of the treatment and at least one time after treatment. Comparison of the images at the end and after treatment allows the risk of recurrence of an inflammatory condition after an anti-inflammatory treatment to be monitored.
- the methods and uses according to the invention can also be used to monitor the response to a treatment of a subject suffering from an inflammatory condition. For example, this can be achieved by repeating the method at least two times, for example one time before treatment and at least two times during the treatment, or at least two times during the treatment. For example, an image of a biological sample and/or of the subject or at least one part of the subject is generated before treatment and at least one time during the treatment, for example with an anti-inflammatory treatment. Comparison of the images before and during treatment allows the response of the subject to that particular treatment to be monitored.
- An increased presence, localization and/or amount of CD31 shed may indicate that the treatment is not or not any more efficient.
- a stable or a decreased presence, localization and/or amount of CD31 shed may indicate that the treatment is efficient.
- Said treatment may be a curative or preventive treatment.
- Said treatment may comprise or consist in administering at least one anti-inflammatory agent, at least one immunosuppressant, at least one probiotic (i.e. live microorganisms that may confer a health benefit on the subject), at least one antibiotic or their combinations.
- at least one anti-inflammatory agent at least one immunosuppressant, at least one probiotic (i.e. live microorganisms that may confer a health benefit on the subject), at least one antibiotic or their combinations.
- the present invention also relates to a method for imaging of inflammation sites using a labeled CD31 shed ligand as defined above.
- the present invention also relates to a method, preferably an in vitro method, for determining whether a subject suffers from an inflammatory condition, is at risk of having an inflammatory condition or is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment or for monitoring the efficacy of a treatment of an inflammatory condition in a subject, wherein said method comprises detecting the presence of CD31 shed on the surface of cells with a labeled CD31 shed ligand as defined above in a biological sample of the subject.
- the cells are preferably platelets, leukocytes and/or endothelial cells.
- biological sample any sample able to contain endothelial cells, platelets or leukocytes, such as a blood sample or fraction thereof (for example a thrombus) or a tissue sample, for example a biopsy.
- the method may comprise a first step of providing a biological sample from the subject.
- the present invention also relates to a method as defined above, wherein the detection of CD31 shed on the surface of the cells in said biological sample indicates that the subject suffers, is at risk of having or developing an inflammatory condition or is at risk of recurrence of an inflammatory condition.
- the present invention also relates to a method as defined above, wherein the amount of CD31 shed detected on the surface of the cells in said biological sample is compared to a reference value or a control biological sample.
- a reference value or a control biological sample corresponds to a healthy subject, in particular a subject that does not suffer from an inflammatory condition or a panel of healthy subjects
- an amount of CD31 shed detected in the biological sample that is greater than those of reference value or of the control biological sample indicates that the subject suffers, is at risk of having or developing an inflammatory condition or is at risk of recurrence of an inflammatory condition.
- the present invention also relates to a method as defined above, wherein an increased amount of CD31 shed detected on the surface of the cells in said biological sample by comparison to the amount detected in a biological sample before treatment or earlier during treatment indicates that said treatment is not efficient and/or wherein a stable or a decreased amount of CD31 shed detected on the surface of the cells in said biological sample by comparison to the amount detected in a biological sample before treatment or earlier during treatment indicates that said treatment is efficient.
- Said method may further comprise determining the amount of CD31 shed on the surface of cells.
- the detection of CD31 shed on the surface of the cells in said biological sample is preferably carried out by imaging techniques.
- the step of detection as mentioned above comprises contacting the biological sample of the subject with a labeled CD31 shed ligand, preferably an effective amount of a labeled CD31 shed ligand, as a molecular imaging agent.
- the present invention also relates to a method as defined above, wherein said method comprises:
- the contact is preferably carried out under conditions that allow the molecular imaging agent (1) to reach the cells of the subject that may express CD31 shed (preferably endothelial cells, platelets and/or leukocyte) and (2) to interact with such CD31 shed , so that the interaction results in the binding of the molecular imaging agent to the CD31 shed .
- CD31 shed preferably endothelial cells, platelets and/or leukocyte
- the molecular imaging agent bound to CD31 shed present in the subject sample is detected by a molecular imaging technique as disclosed above.
- an “effective amount” is an amount sufficient to allow the molecular imaging agent to complete these three conditions of (1) reaching the cells, (2) interacting with CD31 shed and (3) being detected.
- the present invention also relates to a method for preventing and/or treating an inflammatory condition in a subject in need thereof, wherein said method comprises,
- Said suitable treatment may comprise or consist in administering at least one anti-inflammatory agent, at least one immunosuppressant, at least one probiotic (i.e. live microorganisms that may confer a health benefit on the subject), at least one antibiotic, at least one CD31 shed ligand linked to an active ingredient or their combinations.
- at least one anti-inflammatory agent at least one immunosuppressant, at least one probiotic (i.e. live microorganisms that may confer a health benefit on the subject), at least one antibiotic, at least one CD31 shed ligand linked to an active ingredient or their combinations.
- the present invention also relates to a method for preventing and/or treating an inflammatory condition in a subject in need thereof, wherein said method comprises administering to said subject a CD31 shed ligand linked to an active ingredient.
- the active ingredient is for example a drug, such as an anti-inflammatory agent.
- the CD31 shed ligand is thereby used as a drug targeting agent and allows improving the effect of said drug.
- composition comprising the Molecular Imaging Agent
- the pharmaceutical composition according to the invention comprises at least one labeled CD31 shed ligand and at least one pharmaceutically acceptable carrier.
- the term “pharmaceutically acceptable carrier” refers to a carrier medium which does not interfere with the effectiveness of the biological activity of the active ingredient, i.e. the molecular imaging agent, and which is not excessively toxic to the subject at the concentration(s) at which it is administered.
- This term includes solvent(s), dispersion medium/media, coating(s), antibacterial and/or antifungal agent(s), isotonic agent(s), adsorption delaying agent(s) and their combinations.
- the use of such medium/media and/or agent(s) for pharmaceutically active substance(s) is well known in the art.
- the pharmaceutical composition may be administered by injection.
- the pharmaceutical composition comprising the molecular imaging agent may be formulated as sterile aqueous or non-aqueous solution or alternatively as sterile powder for the extemporaneous preparation of a sterile injectable solution.
- the pharmaceutical composition should be stable under the conditions of manufacture and storage, and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- Pharmaceutically acceptable carrier(s) for administration by injection are solvent(s) or dispersion medium/media, such as aqueous solution(s) (e.g., Hank's solution, alcoholic/aqueous solution or saline solution), and non-aqueous carrier(s) (e.g. propylene glycol, polyethylene glycol, vegetable oil and injectable organic esters such as ethyl oleate).
- aqueous solution(s) e.g., Hank's solution, alcoholic/aqueous solution or saline solution
- non-aqueous carrier(s) e.g. propylene glycol, polyethylene glycol, vegetable oil and injectable organic esters such as ethyl oleate.
- the injectable pharmaceutical composition may also contain parenteral vehicle(s) (such as sodium chloride and Ringer's dextrose) and/or intravenous vehicle(s) (such as fluid and nutrient replenishers); as well as other conventional, pharmaceutically acceptable, non-toxic excipient(s) and additive(s) including salt(s), buffer(s) and preservative(s) such as antibacterial and/or antifungal agent(s) (e.g. parabens, chlorobutanol, phenol, sorbic acid, thirmerosal and the like).
- Prolonged absorption of the injectable composition can be brought about by adding agents that can delay absorption (e.g. aluminum monostearate and/or gelatin).
- the pH and concentration of the various components can readily be determined by those skilled in the art.
- the sterile injectable solution may be prepared by incorporating the active compound(s), i.e. the molecular imaging agent, and other ingredient(s) in the required amount of an appropriate solvent and then by sterilizing the resulting mixture, for example, by filtration and/or irradiation.
- the dosage of the molecular imaging agent will vary depending on considerations such as age, sex and weight of the subject, as well as the particular inflammatory condition suspected to affect the patient, the extent of the disease, the tissue(s) of the body to be examined and/or the sensitivity of the imaging label.
- Factors such as contraindications, therapies, and other variables are also to be taken into account to adjust the dosage of molecular imaging agent to be administered. This, however, can be readily achieved by a trained physician.
- one suitable dose of molecular imaging agent i.e. of labeled CD31 shed ligand, or a pharmaceutical composition comprising thereof, corresponds to the lowest amount of molecular imaging agent or pharmaceutical composition that is sufficient to allow molecular imaging of any relevant CD31 shed present in the subject.
- administration be intravenous, intramuscular, intraperitoneal or subcutaneous, and preferably proximal to the site to be examined.
- the present invention also provides a kit comprising material(s) useful for carrying out the methods and uses of the invention.
- the kit comprises at least one CD31 shed ligand as above described and at least one imaging label, preferably at least one radionuclide, and, optionally, instructions for associating said CD31 shed ligand and said imaging label, preferably radionuclide, to form a labeled CD31 shed ligand according to the invention.
- the radionuclide is preferably a short-lived radionuclide, such as technetium-99m (99mTc), gallium-67 (67Ga), yttrium-90 (90Y), indium-111 (111In), rhenium-186 (186Re), and thallium-201 (201TI), more preferably 99mTc.
- 99mTc technetium-99m
- 67Ga gallium-67
- yttrium-90 90Y
- rhenium-186 (186Re) thallium-201
- 201TI thallium-201
- kit may further comprise at least one co-ligand, such as tricine and/or ethylendiaminediacetic acid (EDDA).
- co-ligand such as tricine and/or ethylendiaminediacetic acid (EDDA).
- the kit may further comprise one or more of: labelling buffer, labelling reagent, purification buffer, purification reagent, purification means, injection medium, and/or injection reagent. Protocols for using these buffer(s), reagent(s) and/or means for performing different steps of the preparation procedure and/or administration may be included in the kit.
- the different components included in the kit may be supplied in a solid (e.g. lyophilized) or liquid form.
- the kit may optionally comprise different containers (e.g. vial, ampoule, test tube, flask or bottle) for each individual component.
- Each component will generally be suitable as aliquoted in its respective container or provided in a concentrated form.
- Other containers suitable for conducting certain steps of the preparation methods may also be provided.
- the individual containers of the kit are preferably maintained in close confinement for commercial sale.
- the kit further comprises instructions for using its components for the imaging of an inflammatory condition as described herein, and in particular for determining whether a subject suffers from, is at risk of having or developing an inflammatory condition or is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment, as described herein.
- kit may comprise instructions for preparing labeled CD31 shed ligand from the CD31 shed ligand and the imaging label, instructions concerning dosage and mode of administration of the molecular imaging agent thereby obtained, instructions for performing the detection of CD31 shed , and/or instructions for interpreting the results obtained.
- a kit may also contain a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products.
- FIG. 2 Radio-HPLC stability study of 99mTc-HYNIC-P8RI with tricine/EDDA as coligands.
- A plasma stability after 4 h of incubation in human plasma.
- B Radio-HPLC chromatogram of urine collected in a rat bladder 1 hour after injection of 74 MBq of 99mTc-HYNIC-P8RI with tricine/EDDA as coligands.
- FIG. 3 SPECT/CT images of [99mTc]EDDA/HYNIC-P8RI in a male wistar rat with an abdominal aortic aneurysm (AAA) receiving injection of Porphyromonas gingivalis weekly. Images were acquired 30 min after a tracer injection of 74 MBq and 21 days after AAA surgery. The axial (A), coronal (B) and sagittal (C) planes of the abdominal region are shown. It is observed the tracer elimination via kidneys (white arrows in B) and the bladder (white arrow in C). Focal uptake of [99mTc]EDDA/HYNIC-P8RI can be observed at the location of the AAA (black arrows in A, B, C).
- SEQ ID NO: 1 corresponds to the sequence of human CD31.
- SEQ ID NO: 2 corresponds to the sequence LAPWKK of a 6 amino acid peptide derived from human or murine CD31.
- SEQ ID NO: 3 corresponds to the sequence VRVFLAPWKK of a 10 amino acid peptide derived from murine CD31, also called PepReg CD31.
- SEQ ID NO: 4 corresponds to the sequence VRVILAPWKK of a 10 amino acid peptide derived from human CD31.
- SEQ ID NO: 5 corresponds to the sequence RVFLAPWK of a 8 amino acid peptide derived from murine CD31, also called P8F.
- SEQ ID NO: 6 corresponds to the sequence kwpalfvr of a 8 amino acid peptide, also called P8RI, having the inverted sequence of SEQ ID NO: 5 and consisting of D-amino acids.
- SEQ ID NO: 7 corresponds to the sequence RVILAPWK of a 8 amino acid peptide derived from human CD31.
- SEQ ID NO: 8 corresponds to the sequence kwpalivr of a 8 amino acid peptide having the inverted sequence of SEQ ID NO: 7 and consisting of D-amino acids.
- SEQ ID NO: 9 corresponds to the sequence of murine CD31.
- SEQ ID NO: 10 corresponds to the sequence of bovine CD31.
- SEQ ID NO: 11 corresponds to the sequence of pig CD31.
- SEQ ID NO: 12 corresponds to the amino acids 579 to 601 of sequence SEQ ID NO: 1.
- Sequences SEQ ID NO: 13 to 74 are as defined above.
- P8RI H-kwpalfvr-OH
- HYNIC- P8RI was prepared by solid phase peptide synthesis using Fmoc chemistry (yield after RP-HPLC purification 52%, purity by RP-HPLC 96%).
- Na 99m TcO 4 ⁇ was obtained from a commercial 99 Mo/ 99m Tc generator (TEKCIS®, Iba molecular, France).
- a Dionex Ultimate 3000 system coupled to a Berthold radiometric detector was used for RP-HPLC analysis.
- Protein binding of the purified radiolabeled peptide was determined after 0 min, 30 min, 1 hour, 2 hours and 4 hours of incubation in fresh human plasma at 37° C. and analyzed after size exclusion chromatography (illustra Microspin G-50 Columns, Sephadex G-50, GE Healthcare, UK). G-50 columns were prespun at 2000 ⁇ g for 1 min then 20 ⁇ L of mixture was added and the column was centrifuged at 2000 ⁇ g for 2 min. Protein binding of the radiolabeled peptide was estimated by measuring columns and eluates in a gamma-counter (Cobra II, Packard Bioscience). In the same time, radiolabeled peptide was incubated for 1 h in PBS 1 ⁇ at 37° C. as a control.
- Rat model of vascular inflammation that has been set up at the laboratory: the experimental abdominal aorta aneurysm (AAA) induced by local infusion of elastase and followed by intravenous injection of a periodontal bacterium present in human AAA (Porphyromonas gingivalis) and known to induce AAA inflammation (Delbosc et al., 2011, PLoS ONE 6(4): e18679. doi:10.1371/journal.pone.0018679).
- AAA abdominal aorta aneurysm
- Rat model of hindlimb inflammation was induced by intramuscular injection of turpentine oil (150 ⁇ l) in the right hindlimb, whereas a saline solution (150 ⁇ l) was injected in the left hindlimb (contralateral control).
- HYNIC 6-Hydrazinopyridine-3-carboxylic acid
- HYNIC-P8RI was then labeled at high specific activities (>71 GBq/ ⁇ mol) using tricine, EDDA or Tricine/EDDA as coligands. Labelling yields varied from 65.5% to 98.3% as shown in Table 2. The tricine/EDDA exchange labeling strategy was chosen because of high labeling yield and resulting in a single major specie as analyzed by HPLC (see FIG. 1 ).
- 99m Tc- HYNIC-P8RI was further assessed in a rat model of right hindlimb inflammation using turpentine oil.
- Mertiatide is a non-specific marker of renal function and was used as a negative control, because of its biodistribution pattern close to peptide P8RI (in particular, low molecular weight and quick clearance).
- the technetium-99m radiolabeled P8RI uptake ratio between the turpentine oil injected hindlimb and the saline injected hindlimb was higher compared to the control group injected with technetium-99m radiolabeled mertiatide, thereby confirming the specific binding of P8RI to inflammatory sites (see FIG. 4 ).
- the RCP of [99mTc]EDDA/HYNIC-P8RI was >93% (HPLC and ITLC) without any purification and the specific activity was >71 GBq/pmol. There was no significant release of degraded radiolabelled peptide (RCP>89%) and the radiotracer binding to plasma proteins was very low ( ⁇ 5% after 4 h incubation). In vivo, blood clearance of the tracer was almost exclusively renal with a peak activity in kidneys and bladder 1 h after injection, corresponding to the unaltered form of the peptide on HPLC. In addition, 99m Tc-HYNIC-P8RI uptake by AAA was detectable from 30 min after injection in animals and associated with activated platelets and leukocytes on immunohistochemistry.
- 99m Tc-HYNIC-P8RI was also specifically detected in inflammatory sites in a model of right hindlimb inflammation.
- activated cells involved in inflammation expressing truncated CD31 (CD31 shed ) and with a rapid blood clearance constitutes a useful novel approach in inflammation imaging.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
Description
- The present invention relates to the molecular imaging of inflammatory sites, in particular for determining whether a subject suffers or is at risk of having or developing an inflammatory condition and for monitoring the changes in the extent of an inflammatory condition after an anti-inflammatory treatment.
- Imaging of inflammation sites would be a useful tool for the diagnosis of an inflammation condition. The high level of glucose metabolism in inflammation has prompted to the use of 18F-FDG (2-deoxy-2-18F-fluoro-D-glucose) PET. 18F-FDG however suffers from poor specificity and its high physiologic uptake in the heart, lung and brain limits its use. More specific targets for imaging inflamed tissues are therefore needed.
- CD31 is a transmembrane glycoprotein receptor constitutively expressed by leukocytes, platelets and endothelial cells. It consists of a single chain molecule comprising six Ig-like extracellular domains, a short transmembrane segment and a cytoplasmic tail comprising two important tyrosine-based motifs (around Y663 and Y686) that act as Immunoreceptor Tyrosine-based Inhibitory Motifs (ITIMs). The structure of CD31 is shown in the Table 1 below.
-
TABLE 1 Structure of CD31 Domain Position on SEQ ID NO : 1 Signal peptide 1 to 27 Extracellular domain 28 to 601 First Ig-like extracellular domain 34 to 121 Second Ig-like extracellular domain 145 to 233 Third Ig-like extracellular domain 236 to 315 Fourth Ig-like extracellular domain 328 to 401 Fifth Ig-like extracellular domain 424 to 493 Sixth Ig-like extracellular domain 499 to 591 Juxta-membrane domain 592 to 601 Transmembrane domain 602 to 620 Cytoplasmic domain 621 to 738 - Due to its homophilic and inhibitory functions, CD31 exerts a crucial role in the homeostasis of the circulation. In pro-inflammatory conditions, the homophilic portion of the receptor is lost due to a cleavage and activated cells express a truncated form of CD31. WO2010/000756 indeed discloses that CD31 is shed on activated/memory T lymphocytes between the 5th and the 6th extracellular Ig-like domains whereas WO2013/152919 discloses that activated platelets also express a CD31 that is truncated between the 6th extracellular domain and the juxtamembrane sequence. Both types of shed extracellular sequences of CD31 (referred to as “soluble CD31”) are then released into the circulation, where they are present together with a soluble splice variant of CD31, produced by healthy endothelial cells. The remaining small CD31 ectodomain which remains anchored to the membrane after shedding is referred to as “CD31shed”. WO2010/000756 and WO2013/152919 discloses a method for diagnosing a thrombotic or an autoimmune disorder based on the detection of said soluble CD31 in a biological sample of an individual.
- WO2010/000741 discloses peptides corresponding to juxta-membrane amino acids of the ectodomain of CD31 that are able to rescue the physiological immunoregulatory function of CD31, by specifically targeting CD31shed on activated leukocytes and platelets. Such peptides are useful for the treatment of thrombotic or autoimmune disorders. WO2013/190014 further discloses specific peptides of 8 amino acids, within the membrane juxta-proximal part of extracellular CD31, which hold useful for the treatment of thrombotic or inflammatory disorders and display physic-chemical properties that are more suitable for drug development.
- There is still a need to provide reliable solutions for the imaging and diagnostic of inflammatory conditions.
- The Inventors have unexpectedly found that CD31shed itself can be used as a molecular target for the diagnosis of an inflammatory condition, in particular by allowing the molecular imaging of inflammatory sites. CD31shed was indeed surprisingly found to be present on activated cells in a quantity allowing to obtain a detectable signal when using a labeled CD31shed ligand, whereas the noise signal corresponding to CD31shed present on activated circulating cells and on other organs or cells not involved in inflammation was little, thereby leading to a good signal to noise ratio. They have indeed shown in vivo in an animal model of inflammation that administering to said animal a radiolabeled CD31shed ligand specific for CD31shed allows localizing the inflammation site, due to the specific binding of the radiolabeled CD31shed ligand to the activated cells expressing CD31shed and its subsequent concentration in the inflammation site, whereas the remaining radiolabeled CD31shed ligand is rapidly cleared from the body of the animal.
- In this context, the Inventors used peptide P8RI of sequence SEQ ID NO: 6 consisting of D-enantiomer amino acids coupled to HYNIC (6-Hydrazinopyridine-3-carboxylic acid) via a PEG spacer and radiolabeled with 99mTc. Said radiolabeled CD31shed ligand was found stable both in vitro and in vivo and specific to CD31shed, with very low binding to plasma proteins.
- Therefore, labelled CD31shed ligands, in particular small peptides, able to specifically bind to CD31shed are useful as a tracer for molecular imaging of inflammation.
- One object of the present invention is thus a labeled CD31shed ligand comprising a CD31shed ligand and at least one imaging label, preferably at least one radionuclide.
- Said CD31shed ligand is preferably:
-
- a) a peptide selected in the group consisting of:
- (i) a peptide consisting of a fragment of 3 to 15 amino acids of the sequence defined by amino acids 579 to 601 of sequence SEQ ID NO: 1,
- (ii) a peptide consisting of a fragment of 3 to 15 amino acids of a sequence corresponding to the amino acids 579 to 601 of sequence SEQ ID NO: 1 in a non-human mammalian CD31,
- (iii) a peptide of 3 to 15 amino acids consisting of a sequence at least 70% identical to the sequence of peptide (i),
- (iv) a peptide consisting of a retro-inverso sequence of peptide (i), (ii) or (iii), and
- (v) the peptide (i), (ii), (iii) or (iv) comprising at least one or at least one further chemical modification,
- or
- b) a peptidomimetic of peptide a).
- a) a peptide selected in the group consisting of:
- The CD31shed ligand of (v) preferably comprises at least one amino acid in the D-enantiomer form.
- The CD31shed ligand is preferably selected in the group consisting of a peptide of sequence SEQ ID NO: 2, a peptide of sequence SEQ ID NO: 3, a peptide of sequence SEQ ID NO: 4, a peptide of sequence SEQ ID NO: 5, a peptide of sequence SEQ ID NO: 6 consisting of D-enantiomer amino acids, a peptide of sequence SEQ ID NO: 7 and a peptide of sequence SEQ ID NO: 8 consisting of D-enantiomer amino acids.
- A preferred CD31shed ligand is a peptide of sequence SEQ ID NO: 5, or a peptide of sequence SEQ ID NO: 6 consisting of D-enantiomer amino acids.
- The radionuclide of the labeled CD31shed ligand is preferably detectable by molecular imaging technique(s), such as Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), an hybrid of SPECT and/or PET, or their combinations.
- For example, the radionuclide is technetium-99m (99mTc or 99mTc), gallium-67 (67Ga), gallium-68 (68Ga), yttrium-90 (90Y), indium-111 (111In), rhenium-186 (186Re), fluorine-18 (18F), copper-64 (64Cu) or thallium-201 (201TI).
- A preferred labeled CD31shed ligand comprises a peptide of sequence SEQ ID NO: 6 consisting of D-enantiomer amino acids as CD31shed ligand and 99mTc as radionuclide.
- In one preferred embodiment, the CD31shed ligand is coupled with HYNIC (6-Hydrazinopyridine-3-carboxylic acid), optionally via at least one spacer.
- Another object of the present invention relates to the labeled CD31shed ligand as defined above for use as a molecular imaging agent for imaging of inflammatory sites, in particular for determining whether a subject suffers from an inflammatory condition, is at risk of having an inflammatory condition or is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment or for monitoring the efficacy of a treatment of an inflammatory condition. The present invention also relates to the use of the labeled CD31shed ligand as defined above as a molecular imaging agent, in particular for imaging inflammation sites.
- Another object of the present invention relates to a method, preferably an in vitro method, for determining whether a subject suffers from an inflammatory condition, is at risk of having an inflammatory condition or is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment or for monitoring the efficacy of a treatment of an inflammatory condition, wherein said method comprises:
- detecting the presence of CD31shed on the surface of cells with a labeled CD31shed ligand as defined above in a biological sample obtained from the subject.
- Another object of the present invention relates to CD31shed for use as a molecular imaging target for imaging of inflammatory sites, more particularly for determining whether a subject suffers from an inflammatory condition, is at risk of having an inflammatory condition, is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment or for monitoring the efficacy of a treatment of an inflammatory condition. The present invention also relates to the use of CD31shed for use as a molecular imaging target, in particular for imaging inflammation sites.
- Inflammatory Condition
- An inflammatory condition underlies a large number of diseases. For example, the immune system is often involved with inflammatory conditions, as demonstrated in both allergic reactions and some myopathies, with many immune system disorders resulting in abnormal inflammation.
- As used throughout the present specification, the term “inflammatory condition” includes but is not limited to a chronic inflammatory condition, an immune disorder, an autoimmune disorder, an acute and chronic grant alloimmune conditions, an acute and chronic infectious-driven inflammatory condition, a non-immune disease with etiological origins in inflammatory processes or their combinations.
- The chronic inflammatory condition is for example inflammatory bowel disease, psoriasis, atopic dermatitis, cerebral amyloid angiopathy an/or vasculitis.
- An immune disorder is for example allergies and/or myopathy.
- The autoimmune disorder is for example rheumatoid arthritis (RA), multiple sclerosis (MS), inflammatory bowel disease (IBD), systemic lupus erythematodes (SLE), Graves' disease and/or diabetes mellitus.
- Acute and chronic alloimmune conditions are for example allograft rejection or graft versus host disease (GVHD).
- Acute and chronic infectious-driven inflammatory conditions include the formation of septic granulomas (abscess) and/or septic shock.
- The non-immune disease with etiological origins in inflammatory processes is for example cancer, thrombosis, ischaemic and/or ischemia-reperfusion organ damage (for example heart and/or brain infarction) arterial inflammatory condition (such as atherothrombosis, arterial dissection and/or unhealed/thromboses arterial aneurysm) and/or neurodegenerative disease.
- The inflammatory condition is for example selected from the group consisting of rheumatoid arthritis, multiple sclerosis, allergies, myopathy, inflammatory bowel disease, psoriasis, atopic dermatitis, cerebral amyloid angiopathy, vasculitis, systemic lupus erythematosus, Graves' disease, diabetes mellitus, acute or chronic graft rejection, cancer, thrombosis, atherothrombosis, ischaemic heart and/or brain infarction, and/or neurodegenerative disease.
- Subject for Imaging, to be Diagnosed and/or Treated
- A “subject” in the context of the present invention is a human being or a non-human mammal.
- The terms “human being”, “individual” or “patient” are herein synonymous and may be used interchangeably.
- Said human being may be of any sex, for example male or female and of any age, for example an infant, child, adolescent, adult, elderly people.
- A non-human mammal is preferably a mouse, rat, cat, dog, rabbit, hamster, swine, sheep, horse or primate.
- The subject may suffer from an inflammatory condition, be suspected to suffer from an inflammatory condition, be at risk of having an inflammatory condition or be at risk of recurrence of an inflammatory condition.
- The expressions “at risk of having an inflammatory condition”, “at risk of suffering from an inflammatory condition” and “at risks of developing an inflammatory condition” are herein synonymous.
- “Risk” in the context of the present invention, relates to the probability that an event will occur over a specific time period, for example the conversion to an inflammatory condition.
- Imaging of Inflammation
- The expressions “imaging of inflammation sites” and “imaging of inflammation” are herein synonymous.
- Imaging of inflammation sites allows to localize the inflamed tissues and/or inflamed organs in the body of a subject.
- Imaging of inflammation sites presents many advantages.
- For example, imaging of inflammation sites allows diagnosing an inflammation condition, confirming an inflammation condition, localizing the inflamed tissues or organs, monitoring the response to a treatment, for example to an anti-inflammatory treatment, monitoring the inflammatory side-effects of a treatment, predicting the risk of developing an inflammatory condition and/or determining the risk of recurrence of an inflammatory condition after an anti-inflammatory treatment.
- Imaging of inflammation sites may thus be used for determining whether a subject suffers from an inflammatory condition, is at risk of having an inflammatory condition, is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment or for monitoring the efficacy of a treatment of an inflammatory condition.
- A molecular imaging target and/or a molecular imaging agent are needed to carry out imaging of inflammation.
- As used herein, the term “molecular imaging target” refers to a compound that can be detected by using molecular imaging techniques.
- As used herein, the term “molecular imaging agent” refers to a compound that can be used to detect specific biological elements, in particular a molecular imaging target, by using molecular imaging techniques.
- The molecular imaging agent is preferably an agent coupled to an imaging label, covalently or non-covalently.
- In the context of the invention, the molecular imaging agent is used to detect CD31shed in vivo or in vitro, for example in a blood sample of a subject.
- CD31shed for Use as a Molecular Imaging Target
- The present invention thus relates to CD31shed for use as a molecular imaging target for imaging of inflammation sites.
- The present invention also relates to the use of CD31shed as a molecular imaging target for imaging of inflammation sites.
- The present invention particularly relates to CD31shed for use as a molecular imaging target in a method for imaging inflammation sites, particularly in vivo.
- As used herein “CD31shed” refers to the remaining small CD31 ectodomain which remains anchored to the membrane of endothelial cells, platelets or leukocytes, after shedding of the CD31 transmembrane glycoprotein receptor.
- CD31shed on the surface of activated endothelial cells, platelets and leukocytes lacks at least the 1st to 5th extracellular Ig-like domains of CD31.
- CD31shed on the surface of activated platelets and activated endothelial cells lacks the 1st to 5th extracellular Ig-like domains of CD31 and at least one part of the 6th extracellular Ig-like domain.
- CD31shed on the surface of activated leukocytes lacks the 1st to 5th extracellular Ig-like domains, but comprises the 6th extracellular Ig-like domain.
- The present invention also relates to CD31shed for use as defined above, in a method, preferably an in vivo method, for determining whether a subject suffers from an inflammatory condition, is at risk of having an inflammatory condition, is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment or for monitoring the efficacy of a treatment of an inflammatory condition.
- The present invention also relates to CD31shed for use for determining whether a subject suffers from an inflammatory condition, is at risk of having an inflammatory condition, is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment or for monitoring the efficacy of a treatment of an inflammatory condition, in particular in vivo.
- The expression “inflammatory condition” and “imaging of inflammation sites” are as defined above.
- CD31shed Ligand
- The term “CD31shed ligand” refers to any compound that is able to specifically bind with CD31shed.
- The specific binding of a compound to CD31shed present on a cell surface may be assessed by any method well-known by the skilled person.
- For example, the specific binding may be measured by plasmon surface resonance, flow cytometry or beta-imager.
- In a preferred embodiment, the binding of a compound to be tested to CD31shed present on a cell surface is assessed as follows: the compound to be tested, or an irrelevant analogue as negative control, is bound to a fluorescent probe (e.g. fluoresceine). The compound is incubated at consecutive dilutions (for example 1, 10, 100 μmol) with CD31+ cells (for example from a cell line, such as Jurkat T cells, or primary cells, such as peripheral blood T cells), at a density of 106 cells/ml in a saline buffer comprising Ca++ and Mg++ (HBSS, culture medium). Parallel conditions are incubated in the presence of a cell activator (e.g. TCR crosslinking, such as 1 μg/ml anti-CD3e antibodies+20 μg/ml secondary F(ab′)2 fragment if the cells are T lymphocytes). The reaction is stopped after 5 or 20 minutes by repeated washing steps with cold buffer. Cells are fixed with paraformaldehyde and washed again. Binding of the compound to be tested on individual cells is detected by the relative fluorescent signal using a flow cytometer. A greater signal for the specific compound as compared to the control and in the conditions comprising the cell activator as compared to resting cells indicates appropriate binding to CD31shed.
- Alternatively, the compound to be tested, or an irrelevant analogue as negative control, is tested for its binding to activated endothelial cells (for example primary cells from human blood vessels of immortalized cell lines). The cells are cultured on collagen type I thin layer to confluence. For the activation, the cells are incubated with 20 ng/ml Human recombinant TNFa for 30 minutes in culture medium. The reaction is stopped by rinsing the cells with cold saline buffer and the cells are fixed (for instance with a Zinc-fixative solution for 10 minutes at room temperature). After extensive rinsing in a saline buffer comprising, activated endothelial cells are labeled by the compound to be tested, or an irrelevant analogue as negative control, is bound to a fluorescent probe (e.g. fluoresceine) and counterstained by a plasma membrane dye (e g Cell Mask™) and a nuclear staining (eg Hoechst 33342). Binding of the compound to be tested on individual cells is detected by the relative fluorescent signal using a fluorescence microscope. A greater signal for the specific compound as compared to the control and in the conditions comprising the cell activator as compared to resting cells indicates appropriate binding to CD31shed.
- The CD31shed ligand may be a peptide, a peptidomimetic, a chemical compound, an antibody or an aptamer.
- The term “antibody” is thus used to refer to any antibody-like molecule that has an antigen binding region, and this term includes antibody fragments that comprise an antigen binding domain such as Fab′, Fab, F(ab′)2, single domain antibodies (DABs or VHH), TandAbs dimer, Fv, scFv (single chain Fv), dsFv, ds-scFv, Fd, linear antibodies, minibodies, diabodies, bispecific antibody fragments, bibody, tribody (scFv-Fab fusions, bispecific or trispecific, respectively); sc-diabody; kappa(lamda) bodies (scFv-CL fusions); DVD-Ig (dual variable domain antibody, bispecific format); SIP (small immunoprotein, a kind of minibody); SMIP (“small modular immunopharmaceutical” scFv-Fc dimer; DART (ds-stabilized diabody “Dual Affinity ReTargeting”); small antibody mimetics comprising one or more CDRs and the like. The techniques for preparing and using various antibody-based constructs and fragments are well known in the art. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is non-internalizing. As used herein the term “non-internalizing antibody” refers to an antibody, respectively, that has the property of to bind to a target antigen present on a cell surface, and that, when bound to its target antigen, does not enter the cell and become degraded in the lysosome. In some embodiments, the heterologous polypeptide is a light immunoglobulin chain. In some embodiments, the heterologous polypeptide is a heavy immunoglobulin chain. In some embodiments, the heterologous polypeptide is a heavy single heavy chain variable domain of antibodies of the type that can be found in Camelid mammals which are naturally devoid of light chains.
- Particularly, in the context of the invention, the antibody is a single domain antibody. The term “single domain antibody” has its general meaning in the art and refers to the single heavy chain variable domain of antibodies of the type that can be found in Camelid mammals which are naturally devoid of light chains. Such single domain antibody are also called VHH or “nanobody®”. For a general description of (single) domain antibodies, reference is also made to the prior art cited above, as well as to
EP 0 368 684, Ward et al. (Nature 1989 Oct 12; 341 (6242): 544-6), Holt et al., Trends Biotechnol., 2003, 21(11):484-490; and WO 06/030220, WO 06/003388. The amino acid sequence and structure of a single domain antibody can be considered to be comprised of four framework regions or “FRs” which are referred to in the art and herein as “Framework region 1” or “FRI”; as “Framework region 2” or “FR2”; as “Framework region 3” or “FR3”; and as “Framework region 4” or “FR4” respectively; which framework regions are interrupted by three complementary determining regions or “CDRs”, which are referred to in the art as “Complementarity Determining Region for “CDRI”; as “Complementarity Determining Region 1” or “CDR2” and as “Complementarity Determining Region 2” or “CDR3” and as “Complementarity Determining Region 2”, respectively. Accordingly, the single domain antibody can be defined as an amino acid sequence with the general structure: FRI—CDRI—FR2—CDR2—FR3—CDR3—FR4 in which FRI to FR4 refer toframework regions 1 to 4 respectively, and in which CDRI to CDR3 refer to thecomplementarity determining regions 1 to 3. In the context of the invention, the amino acid residues of the single domain antibody are numbered according to the general numbering for VH domains given by the International ImMunoGeneTics information system aminoacid numbering (http://imgt.cines.fr/). - Particularly, in the context of the invention, the antibody is a single chain variable fragment. The term “single chain variable fragment” or “scFv fragment” refers to a single folded polypeptide comprising the VH and VL domains of an antibody linked through a linker molecule. In such a scFv fragment, the VH and VL domains can be either in the VH—linker—VL or VL—linker—VH order. In addition to facilitate its production, a scFv fragment may contain a tag molecule linked to the scFv via a spacer. A scFv fragment thus comprises the VH and VL domains implicated into antigen recognizing but not the immunogenic constant domains of corresponding antibody.
- In one embodiment of the invention, the CD31shed ligand is a peptide.
- The peptide is preferably a peptide as disclosed in WO2010/000741 or WO2013/190014.
- Preferably, the CD31shed ligand is a synthetic peptide.
- By a “synthetic peptide”, it is intended that the peptide is not present within a living organism, e.g. within human body.
- The synthetic peptide is preferably purified.
- The synthetic peptide may be part of a composition or a kit.
- The peptide may be selected in the group consisting of:
-
- (i) a peptide consisting of a fragment of 3 to 15 amino acids of the sequence defined by amino acids 579 to 601 of sequence SEQ ID NO: 1,
- (ii) a peptide consisting of a fragment of 3 to 15 amino acids of a sequence corresponding to the amino acids 579 to 601 of sequence SEQ ID NO: 1 in a non-human mammalian CD31,
- (iii) a peptide of 3 to 15 amino acids consisting of a sequence at least 70% identical to the sequence of peptide (i),
- (iv) a peptide consisting of a retro-inverso sequence of peptide (i), (ii) or (iii), and
- (v) the peptide (i), (ii), (iii) or (iv) comprising at least one or at least one further chemical modification, preferably at least one amino acid in the D-enantiomer form.
- A “fragment” refers herein to a sequence of consecutive amino acids. For example, a fragment may be a fragment of 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids.
- The sequence defined by amino acids 579 to 601 of sequence SEQ ID NO: 1 is sequence SEQ ID NO: 12.
- Thus, the peptide may consist of a fragment of 3 to 15 amino acids of sequence SEQ ID NO: 12.
- The peptide may also consist of a fragment of 3 to 15 amino acids of a sequence corresponding to sequence SEQ ID NO: 12 in a non-human mammalian CD31.
- Non-limiting examples of non-human mammalian CD31 are the murine CD31 of sequence SEQ ID NO: 9, the bovine CD31 of sequence SEQ ID NO: 10 and the pig CD31 of sequence SEQ ID NO: 11.
- The person skilled in the art can easily identify a sequence corresponding to the amino acids 579 to 601 of sequence SEQ ID NO: 1, i.e. to sequence SEQ ID NO: 12, in a non-human mammalian CD31 protein, for example by performing a sequence alignment between sequence SEQ ID NO: 1 and the sequence of said non-human mammalian CD31 protein, for example with one of sequences SEQ ID NO: 9, SEQ ID NO: 10 and SEQ ID NO: 11.
- Methods for sequence alignment and determination of sequence identity are well known in the art, for example using publicly available computer software such as BioPerl, BLAST, BLAST-2, CS-BLAST, FASTA, ALIGN, ALIGN-2, LALIGN, Jaligner, matcher or Megalign (DNASTAR) software and alignment algorithms such as the Needleman-Wunsch and Smith-Waterman algorithms.
- The sequence of the CD31 peptide according to the invention is preferably derived from the sequence of human CD31 or murine CD31.
- The peptide may also be a peptide of 3 to 15 amino acids consisting of a sequence at least 70%, at least 75%, at least 80%, at least 85% or at least 90% identical to the sequence of peptide (i), i.e. to the sequence of a fragment of 3 to 15 amino acids of the sequence defined by amino acids 579 to 601 of sequence SEQ ID NO: 1.
- A peptide sequence at least 70% identical to a given sequence of 4 to 6 amino acids differs from said given sequence of at most one amino acid. A peptide sequence at least 70% identical to a given sequence of 7 to 9 amino acids differs from said given sequence of at most two amino acids.
- A peptide sequence at least 70% identical to a given sequence of 10 to 13 amino acids differs from said given sequence of at most three amino acids.
- A peptide sequence at least 70% identical to a given sequence of 14 or 15 amino acids differs from said given sequence of at most four amino acids.
- By “a sequence at least x % identical to a reference sequence”, it is intended that the amino acid sequence of the subject peptide is identical to the reference sequence or differ from the reference sequence by up to 100-x amino acid alterations per each 100 amino acids of the reference sequence. In other words, to obtain a polypeptide having an amino acid sequence at least x % identical to a reference amino acid sequence, up to 100-x % of the amino acid residues in the subject sequence may be inserted, deleted or substituted with another amino acid.
- Methods for comparing the identity of two or more sequences are well known in the art. For instance, programs available in the Wisconsin Sequence Analysis Package, version 9.1, for example the programs BESTFIT and GAP, may be used to determine the % identity between two polypeptide sequences. BESTFIT uses the “local homology” algorithm of Smith and Waterman and finds the best single region of similarity between two sequences. Other programs for determining identity between sequences are also known in the art, for instance the Needle program, which is based on the Needleman and Wunsch algorithm, described in Needleman and Wunsch (1970) J. Mol Biol. 48:443-453, with for example the following parameters for polypeptide sequence comparison: comparison matrix: BLOSUM62, gap open penalty: 10 and gap extend penalty: 0.5, end gap penalty: false, end gap open penalty=10, end gap extend penalty=0.5; and the following parameters for polynucleotide sequence comparison: comparison matrix: DNAFULL; gap open penalty=10, gap extend penalty=0.5, end gap penalty: false, end gap open penalty=10, end gap extend penalty=0.5.
- Peptides consisting of an amino acid sequence “at least 70%, 75%, 80%, 85%, or 90% identical” to a reference sequence may comprise mutations, such as deletions, insertions and/or substitutions compared to the reference sequence.
- In case of substitutions, the substitution preferably corresponds to a conservative substitution as indicated in the Table 1 below. In a preferred embodiment, the peptide consisting of an amino acid sequence at least 70%, 75%, 80%, 85% or 90% identical to a reference sequence only differs from the reference sequence by conservative substitutions.
-
TABLE 1 Conservative substitutions Type of Amino Acid Ala, Val, Leu, Ile, Met, Pro, Amino acids with aliphatic hydrophobic Phe, Trp side chains Ser, Tyr, Asn, Gln, Cys Amino acids with uncharged but polar side chains Asp, Glu Amino acids with acidic side chains Lys, Arg, His Amino acids with basic side chains Gly Neutral side chain - In another preferred embodiment, the peptide consisting of an amino acid sequence at least 70%, 75%, 80%, 85% or 90% identical to a reference sequence corresponds to a naturally-occurring allelic variant of the reference sequence.
- In still another preferred embodiment, the peptide consisting of an amino acid sequence at least 70%, 75%, 80%, 85%or 90% identical to a reference sequence corresponds to a homologous sequence derived from another non-human mammalian species than the reference sequence.
- In a preferred embodiment, the peptide consisting of an amino acid sequence at least 70%, 75%, 80%, 85% or 90% identical to a reference sequence differs from the reference sequence by conservative substitutions and/or corresponds to a homologous sequence derived from another non-human mammalian species than the reference sequence.
- By the expression “a peptide consisting of a retro-inverso sequence of peptide (i), (ii) or (iii)”, it is herein meant a peptide that differs from the peptide (i), (ii) or (iii) in that its amino acids are in the reverse order by comparison to the sequence of peptide (i), (ii) or (iii), respectively, and consist of D-amino acids instead of the naturally-occurring L-amino acids.
- D-enantiomers of amino acids (also called D-amino acids) are referred to by the same letter as their corresponding L-enantiomer (also called L-amino acid), but in lower case. Thus, for example, the L-enantiomer of arginine is referred to as ‘R’, while the D-enantiomer is referred to as ‘r’.
- Preferably, the peptide is soluble in an organic or nonorganic solvent.
- In a preferred embodiment, the peptide is soluble in water. More particularly, the peptide is preferably soluble in water and/or in aqueous buffer such as trifluoroacetate (for example in a 0.1% trifluoroacetate solution), NaCl 9 g/L, PBS, Tris or Tris-phosphate. The solubility in water and aqueous buffers is particularly advantageous on the pharmacological point of view. Thanks to such solubility, the peptide may be dissolved in an aqueous solution, for example at a concentration equal to, at least of or at most of 1 micromolar, 10 micromolar, 50 micromolar, 100 micromolar, 500 micromolar, 1 mM, 50 mM or 100 mM.
- A CD31shed ligand of the invention that is readily soluble in water may be obtained by the presence of at least one charged amino acid (preferably arginine (R) and/or lysine (K)), wherein said charged amino acid is not comprised between two hydrophobic residues.
- Thus, in a preferred embodiment, the CD31shed ligand according to the invention comprises at least one charged amino acid, preferably arginine and/or lysine, wherein said charged amino acid is not comprised between two hydrophobic residues.
- In a more preferred embodiment, said charged amino acid is located either at the N- or C-terminal end of the sequence.
- For example, the sequence of a preferred CD31shed ligand according to the invention begins with the motif RV (for example instead of VRV).
- In a preferred embodiment, the peptide is resistant to peptidase, in particular to eukaryote peptidase.
- By “resistant to peptidase”, it is herein meant that the CD31shed ligand remains undigested, as determined by reverse phase—high-performance liquid chromatography (RP-HPLC) and mass spectroscopy (MS), upon incubation at 37° C. with mammalian serum or injection in a living laboratory animal. Laboratory tests aimed at evaluating serum stability of the peptides are well standardized (see for example Jenssen and Aspmo, 2008, Methods Mol Biol 494, 177-186). Highly peptidase-resistant peptides are those that remains undigested for up to 70% of their original mass and/or displaying a half life longer than 240 minutes in the presence of proteolytic enzymes (see for example Kumarasinghe and Hruby, 2015, In Peptide Chemistry and Drug Design, B. M. Dunn, ed. (Hoboken, N.J.: Wiley), pp. 247-266).
- The CD31shed ligand is preferably resistant to peptidases present in blood, such as soluble peptidases or peptidases present on cell surface.
- The CD31shed ligand may also comprise at least one or at least one further chemical modification, preferably to improve its stability and/or bioavailability.
- Such chemical modifications generally aim at obtaining peptides with increased protection of the peptides against enzymatic degradation in vivo and/or increased capacity to cross membrane barriers, thus increasing its half-life and/or maintaining or improving its biological activity. Any chemical modification known in the art can be employed according to the present invention.
- The CD31shed ligand may comprise at least one artificial amino acid, said artificial amino acid being preferably selected from the group consisting of a D-enantiomer amino acid, a beta-methyl amino acid, a alpha-substituted alpha-amino acid and an amino acid analog.
- By “beta-methyl amino acid”, it is herein meant a derivative of the amino acid alanine with an aminomethyl group on the side chain. This non-proteinogenic amino acid is classified as a polar base.
- By “alpha-substituted alpha-amino acid”, it is herein meant that the group on the alpha carbon of an L-amino acid (NH2) has been changed to another, non proteinaceous group, such as a methyl-, aryl- or acyl- group.
- By “amino acid analog”, it is herein meant any other artificial analog of a natural amino acid.
- The CD31shed ligand may thus comprise at least one amino acid in the D-enantiomer form. For example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 of the amino acids of the CD31shed ligand defined above may be in the D-enantiomer form.
- In one embodiment, the CD31shed ligand consists of D-amino acids.
- The CD31shed ligand may also comprise an inverted sequence, namely an inversion of the amino acid chain (from the C-terminal end to the N-terminal end). The entire amino acid sequence of the peptide may be inverted, or a portion of the amino acid sequence may be inverted. For example, a consecutive sequence of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids may be inverted. Reference herein to ‘inverted’ amino acids refers to inversion of the sequence of consecutive amino acids in the sequence.
- Other chemical modifications include, but are not limited to:
-
- modifications to the N-terminal and/or C-terminal ends of the peptides such as e.g. N-terminal methylation, N-terminal acylation (preferably acetylation) or deamination, or modification of the C-terminal carboxyl group into an amide or an alcohol group;
- modifications at the amide bond between two amino acids: acylation (preferably acetylation) or alkylation (preferably methylation) at the nitrogen atom or the alpha carbon of the amide bond linking two amino acids;
- modifications at the alpha carbon of the amide bond linking two amino acids such as e.g. acylation (preferably acetylation) or alkylation (preferably methylation) at the alpha carbon of the amide bond linking two amino acids;
- retro-inversions in which one or more naturally-occurring amino acids (L-enantiomer) are replaced with the corresponding D-enantiomers, together with an inversion of the amino acid chain (from the C-terminal end to the N-terminal end);
- azapeptides, in which one or more alpha carbons are replaced with nitrogen atoms; betapeptides, in which the amino group of one or more amino acid is bonded to the β carbon rather than the a carbon,
- ester linkage(s) (such as α-hydroxy acid(s)),
- insertion of extra methylene group(s) (for example β- and γ-amino acid(s), and/or
- Peptoid(s), oligourea(s), arylamide(s) and/or oligohydrazide(s).
- The CD31shed ligand includes amino acids modified either by natural processes, such as post-translational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modification(s) can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini, it will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from natural post-translational processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, araidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidyl inositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutarnate, formylation, gamma-carboxylation, glycosylation, GP6′I anchor formation, hydroxylation, iodination, mefhylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoyiation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.
- In a preferred embodiment of the invention, the CD31shed ligand is selected in the group consisting of:
-
- (i) a peptide consisting of a fragment of 3 to 15 amino acids of the sequence defined by amino acids 579 to 601 of sequence SEQ ID NO: 1, said fragment comprising the amino acids 579 to 581, the amino acids 589 to 591, the amino acids 599 to 601 and/or the amino acids 593 to 595 of SEQ ID NO: 1,
- (ii) a peptide consisting of a fragment of 3 to 15 amino acids of a sequence corresponding to the amino acids 579 to 601 of sequence SEQ ID NO: 1 in a non-human mammalian CD31, for example a fragment of 3 to 15 amino acids of the sequence defined by amino acids 568 to 590 of sequence SEQ ID NO: 9, said fragment preferably comprising the amino acids 568 to 570, the amino acids 578 to 580, the amino acids 588 to 590 and/or the amino acids 582 to 584 of SEQ ID NO: 9,
- (iii) a peptide of 3 to 15 amino acids consisting of a sequence at least 70% identical, preferably at least 75% identical, preferably at least 80% identical, more preferably at least 85% identical, still more preferably at least 90% identical to the sequence of peptide (i),
- (iv) a peptide consisting of a retro-inverso sequence of peptide (i), (ii) or (iii), and
- (v) the peptide (i), (ii), (iii) or (iv) comprising at least one or at least one further chemical modification.
- Such peptide has, for example, a sequence selected from the group consisting of: SSTLAVRVFLAPWKK (SEQ ID NO: 13, amino acids 576 to 590 of SEQ ID NO: 9), STLAVRVFLAPWKK (SEQ ID NO: 14, amino acids 577 to 590 of SEQ ID NO: 9), TLAVRVFLAPWKK (SEQ ID NO: 15, amino acids 578 to 590 of SEQ ID NO: 9), LAVRVFLAPWKK (SEQ ID NO: 16, amino acids 579 to 590 of SEQ ID NO: 9), AVRVFLAPWKK (SEQ ID NO: 17, amino acids 580 to 590 of SEQ ID NO: 9), VRVFLAPWKK (SEQ ID NO: 3, amino acids 581 to 590 of SEQ ID NO: 9), RVFLAPWKK (SEQ ID NO: 18, amino acids 582 to 590 of SEQ ID NO: 9), VFLAPWKK (SEQ ID NO: 19, amino acids 583 to 590 of SEQ ID NO: 9), FLAPWKK (SEQ ID NO: 20, amino acids 584 to 590 of SEQ ID NO: 9), LAPWKK (SEQ ID NO: 2, amino acids 585 to 590 of SEQ ID NO: 9), APWKK (SEQ ID NO: 21, amino acids 586 to 590 of SEQ ID NO: 9), PWKK SEQ ID NO: 22, amino acids 587 to 590 of SEQ ID NO: 9), WKK (amino acids 588 to 590 of SEQ ID NO: 9), SKILTVRVILAPWKK (SEQ ID NO: 23, amino acids 587 to 601 of SEQ ID NO: 1), KILTVRVILAPWKK (SEQ ID NO: 24, amino acids 588 to 601 of SEQ ID NO: 1), ILTVRVILAPWKK (SEQ ID NO: 25, amino acids 589 to 601 of SEQ ID NO: 1), LTVRVILAPWKK (SEQ ID NO: 26, amino acids 590 to 601 of SEQ ID NO: 1), TVRVILAPWKK (SEQ ID NO: 27, amino acids 591 to 601 of SEQ ID NO: 1), VRVILAPWKK (SEQ ID NO: 4, amino acids 592 to 601 of SEQ ID NO: 1), RVILAPWKK (SEQ ID NO: 28, amino acids 593 to 601 of SEQ ID NO: 1), VILAPWKK (SEQ ID NO: 29, amino acids 594 to 601 of SEQ ID NO: 1), ILAPWKK (SEQ ID NO: 30, amino acids 595 to 601 of SEQ ID NO: 1), SSMRTSPRSSTLAVR (SEQ ID NO: 31, amino acids 568 to 582 of SEQ ID NO: 9), SSMRTSPRSSTLAV (SEQ ID NO: 32, amino acids 568 to 581 of SEQ ID NO: 9), SSMRTSPRSSTLA (SEQ ID NO: 33, amino acids 568 to 580 of SEQ ID NO: 9), SSMRTSPRSSTL (SEQ ID NO: 34, amino acids 568 to 579 of SEQ ID NO: 9), SSMRTSPRSST (SEQ ID NO: 35, amino acids 568 to 578 of SEQ ID NO: 9), SSMRTSPRSS (SEQ ID NO: 36, amino acids 568 to 577 of SEQ ID NO: 9), SSMRTSPRS (SEQ ID NO: 37, amino acids 568 to 576 of SEQ ID NO: 9), SSMRTSPR (SEQ ID NO: 38, amino acids 568 to 575 of SEQ ID NO: 9), SSMRTSP (SEQ ID NO: 39, amino acids 568 to 574 of SEQ ID NO: 9), SSMRTS (SEQ ID NO: 40, amino acids 568 to 573 of SEQ ID NO: 9), SSMRT (SEQ ID NO: 41, amino acids 568 to 572 of SEQ ID NO: 9), SSMR (SEQ ID NO: 42, amino acids 568 to 571 of SEQ ID NO: 9), SSM (amino acids 568 to 570 of SEQ ID NO: 9), NHASSVPRSKILTVR (SEQ ID NO: 43, amino acids 579 to 593 of SEQ ID NO: 1), NHASSVPRSKILTV (SEQ ID NO: 44, amino acids 579 to 592 of SEQ ID NO: 1), NHASSVPRSKILT (SEQ ID NO: 45, amino acids 579 to 591 of SEQ ID NO: 1), NHASSVPRSKIL (SEQ ID NO: 46, amino acids 579 to 590 of SEQ ID NO: 1), NHASSVPRSKI (SEQ ID NO: 47, amino acids 579 to 589 of SEQ ID NO: 1), NHASSVPRSK (SEQ ID NO: 48, amino acids 579 to 588 of SEQ ID NO: 1), NHASSVPRS (SEQ ID NO: 49, amino acids 579 to 587 of SEQ ID NO: 1), NHASSVPR (SEQ ID NO: 50, amino acids 579 to 586 of SEQ ID NO: 1), NHASSVP (SEQ ID NO: 51, amino acids 579 to 585 of SEQ ID NO: 1), NHASSV (SEQ ID NO: 52, amino acids 579 to 584 of SEQ ID NO: 1), NHASS (SEQ ID NO: 53, amino acids 579 to 583 of SEQ ID NO: 1), NHAS (SEQ ID NO: 54, amino acids 579 to 582 of SEQ ID NO: 1), NHA (amino acids 579 to 581 of SEQ ID NO: 1), TSPRSSTLAVRVFLA (SEQ ID NO: 55, amino acids 572 to 586 of SEQ ID NO: 9), SPRSSTLAVRVFL (SEQ ID NO: 56, amino acids 573 to 585 of SEQ ID NO: 9), PRSSTLAVRVF (SEQ ID NO: 57, amino acids 574 to 584 of SEQ ID NO: 9), RSSTLAVRV (SEQ ID NO: 58, amino acids 575 to 583 of SEQ ID NO: 9), SSTLAVR (SEQ ID NO: 59, amino acids 576 to 582 of SEQ ID NO: 9), STLAV (SEQ ID NO: 60, amino acids 577 to 581 of SEQ ID NO: 9), TLA (amino acids 578 to 580 of SEQ ID NO: 9), SVPRSKILTVRVILA (SEQ ID NO: 61, amino acids 583 to 597 of SEQ ID NO: 1), VPRSKILTVRVIL (SEQ ID NO: 62, amino acids 584 to 596 of SEQ ID NO: 1), PRSKILTVRVI (SEQ ID NO: 63, amino acids 585 to 595 of SEQ ID NO: 1), RSKILTVRV (SEQ ID NO: 64, amino acids 586 to 594 of SEQ ID NO: 1), SKILTVR (SEQ ID NO: 65, amino acids 587 to 593 of SEQ ID NO: 1), KILTV (SEQ ID NO: 66, amino acids 588 to 562 of SEQ ID NO: 1), ILT (amino acids 589 to 591 of SEQ ID NO: 1), RVF (amino acids 582 to 584 of SEQ ID NO: 9), RVFL (SEQ ID NO: 67, amino acids 582 to 585 of SEQ ID NO: 9), RVFLA (SEQ ID NO: 68, amino acids 582 to 586 of SEQ ID NO: 9), RVFLAP (SEQ ID NO: 69, amino acids 582 to 587 of SEQ ID NO: 9), RVFLAPW (SEQ ID NO: 70, amino acids 582 to 588 of SEQ ID NO: 9), RVFLAPWK (SEQ ID NO: 5, amino acids 582 to 589 of SEQ ID NO: 9), RVI (amino acids 593 to 595 of SEQ ID NO: 1), RVIL (SEQ ID NO: 71, amino acids 593 to 596 of SEQ ID NO: 1), RVILA (SEQ ID NO: 72, amino acids 593 to 597 of SEQ ID NO: 1), RVILAP (SEQ ID NO: 73, amino acids 593 to 598 of SEQ ID NO: 1), RVILAPW (SEQ ID NO: 74, amino acids 593 to 599 of SEQ ID NO: 1), RVILAPWK (SEQ ID NO: 7, amino acids 593 to 600 of SEQ ID NO: 1).
- In a more preferred embodiment of the invention, the CD31shed ligand is selected in the group consisting of:
-
- (i) a peptide consisting of a fragment of 3 to 15 amino acids of the sequence defined by amino acids 579 to 601 of sequence SEQ ID NO: 1, said fragment comprising the amino acids 579 to 582, the amino acids 588 to 592, the amino acids 598 to 601 and/or the amino acids 593 to 595 of SEQ ID NO: 1,
- (ii) a peptide consisting of a fragment of 3 to 15 amino acids of a sequence corresponding to the amino acids 579 to 601 of sequence SEQ ID NO: 1 in a non-human mammalian CD31, for example a fragment of 3 to 15 amino acids of the sequence defined by amino acids 568 to 590 of sequence SEQ ID NO: 9, said fragment preferably comprising the amino acids 568 to 571, the amino acids 578 to 580 the amino acids 587 to 590 and/or the amino acids 582 to 584 of SEQ ID NO: 9,
- (iii) a peptide of 3 to 15 amino acids consisting of a sequence at least 70% identical, preferably at least 75% identical, preferably at least 80% identical, more preferably at least 85% identical, still more preferably at least 90% identical to the sequence of peptide (i),
- (iv) a peptide consisting of a retro-inverso sequence of peptide (i), (ii) or (iii), and
- (v) the peptide (i), (ii), (iii) or (iv) comprising at least one or at least one further chemical modification.
- In a preferred embodiment, the CD31shed ligand is an 8 amino-acid fragment comprising inversions and/or at least one unnatural amino acid, such as at least one D-amino acids. Such peptides indeed retain the activity of the original peptide or even demonstrate improved activity. Incorporation of unnatural amino acids in peptides intended for therapeutic use is of utility in increasing the stability of the peptide, in particular in vivo stability.
- In another preferred embodiment of the invention, the CD31shed ligand is selected in the group consisting of a peptide of sequence SEQ ID NO: 2, a peptide of sequence SEQ ID NO: 3, a peptide of sequence SEQ ID NO: 4, a peptide of sequence SEQ ID NO: 5, a peptide of sequence SEQ ID NO: 6 consisting of D-enantiomer amino acids, a peptide of sequence SEQ ID NO: 7 and a peptide of sequence SEQ ID NO: 8 consisting of D-enantiomer amino acids.
- A more preferred CD31shed ligand is a peptide of sequence SEQ ID NO: 5 or a peptide of sequence SEQ ID NO: 6 consisting of D-enantiomer amino acids.
- The CD31shed ligand may additionally comprise at least one chelating agent.
- A chelating agent is a molecule covalently bound to the ligand, which allows complexing radiometal(s).
- Typically, chelating agents could be: 6-Hydrazinopyridine-3-carboxylic acid (HYNIC), chelating peptide such as Gly-Gly-Cys or His-based sequence (Francesconi 2004, Waibel 1999, Ali 2011), MAG3 en N-ter (Okarvi 2012, 2004), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetracetic acid (DOTA), diethylene triamine penta-acetic acid (DTPA), 1,4,7-tris(carboxymethylaza)cyclododecane-10-azaacetylamide (DO3A), nitrilotriacetic acid (NTA), D-penicillamine, 2,3-dimercaptosuccinic acid,2,3-dimercapto-1-propanesulfonic acid, 2,3-dimercaptopropanol (BAL), triethylenetetramine, ammonium tetrathiomolybdate anion, ethylenediaminetetraacetic acid (EDTA), 2-(p-isothiocyanatobenzyl)-6-methyldiethylenetriaminepentaacetic acid (IB4M) or hydroxypyridinone (HOPO).
- The CD31shed ligand may be linked to the chelating agent directly (for example the chelating agent being attached to a lateral amino acid long chain) or indirectly, for example via at least one spacer.
- A preferred chelating agent is 6-Hydrazinopyridine-3-carboxylic acid (HYNIC).
- In such case, the peptide of the CD31shed ligand may be linked to HYNIC directly (for example HYNIC being attached to a lateral amino acid long chain) or indirectly, for example via at least one spacer.
- The spacer for example comprises or consists of at least one PEG (polyethylene glycol), for example one, two or at least three PEG, more preferably three PEG and/or at least one aliphatic spacer.
- A preferred CD31shed ligand is a compound of the following formula:
- This compound is also called HYNIC-P8RI in the following.
- The CD31shed ligand may be prepared by any well-known procedure in the art, such as chemical synthesis, for example solid phase synthesis or liquid phase synthesis, or genetic engineering. As a solid phase synthesis, for example, the amino acid corresponding to the C-terminus of the peptide to be synthesized is bound to a support which is insoluble in organic solvents, and by alternate repetition of reactions, one wherein amino acids with their amino groups and side chain functional groups protected with appropriate protective groups are condensed one by one in order from the C-terminus to the N-terminus, and one where the amino acids bound to the resin or the protective group of the amino groups of the peptides are released, the peptide chain is thus extended in this manner. After synthesis of the desired peptide, it is subjected to the deprotection reaction and cut out from the solid support. Such peptide cutting reaction may be carried with hydrogen fluoride or tri-fluoromethane sulfonic acid for the Boc method, and with TFA for the Fmoc method.
- Solid phase synthesis methods are largely classified by the tBoc method and the Fmoc method, depending on the type of protective group used. Typically used protective groups include tBoe (t-butoxycarbonyl), CI-Z (2-chlorobenzyloxycarbonyl), Br-Z (2-bromobenzyloyycarbonyl), Bzl (benzyl), Fmoc (9-fluorenylmcthoxycarbonyl), Mbh (4,4′-dimethoxydibenzhydryl), Mtr (4-methoxy-2,3,6-trimethylbenzenesulphonyl), Trt (trityl), Tos (tosyl), Z (benzyloxycarbonyl) and Clz-Bzl (2,6-dichlorobenzyl) for the amino groups; NO2 (nitro) and Pmc (2,2, 5,7, 8-pentamethylchromane-6-sulphonyl) for the guanidino groups); and tBu (t-butyl) for the hydroxyl groups).
- Alternatively, the CD31shed ligand may be synthesized using recombinant techniques.
- The method of producing the CD31shed ligand may optionally comprise the steps of purifying said CD31shed ligand, chemically modifying said CD31shed ligand, and/or formulating said CD31shed ligand into a pharmaceutical composition.
- In an embodiment, the CD31shed ligand is a peptidomimetic of a peptide as defined above, i.e. a compound that mimics said peptide.
- A «peptidomimetic» is a compound consisting of or essentially consisting of non-peptidic structural elements that mimics a given peptide, thereby conferring to said compound a biological activity equal to or similar to said peptide.
- The peptidomimetic is preferably soluble in an organic or nonorganic solvent.
- As the peptide previously, the peptidomimetic is preferably soluble in water.
- Methods for designing and synthesizing peptidomimetics of a given peptide are well-known in the art and include e.g. those described in Ripka and Rich (Curr. Opin. Chem. Biol. 1998; 2(4):441-52) and in Patch and Barron (Curr. Opin. Chem. Biol. 2002; 6(6):872-7).
- Imaging Label
- The labeled CD31shed ligand according to the invention comprises at least one imaging label.
- Said imaging label may be a radionucleide or a contrastophor.
- The term “contrastophor” as used herein refers to a contrast agent, for example comprising a chelating agent.
- Examples of chelating agent that may be used in a contrastophor are given below in the section “CD31shed ligand”.
- Non-limitative examples of contrastophor are Gd-DTPA (complex of gadolinium and DTPA) or Gd-DOTA (complex of gadolinium and DOTA).
- A contrastophor is preferably used in MRI (also called thereafter “IRM” or “Magnetic Resonance Imaging”).
- The term “radionuclide” as used herein has the same meaning as radioactive nuclide, radioisotope or radioactive isotope.
- The radionuclide is preferably detectable by nuclear medicine molecular imaging technique(s), such as, Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), an hybrid of SPECT and/or PET or their combinations.
- Single Photon Emission Computed Tomography (SPECT) herein includes planar scintigraphy (PS).
- An hybrid of SPECT and/or PET is for example SPECT/CT, PET/CT, PET/IRM or SPECT/IRM.
- SPECT and PET acquire information on the concentration (or uptake) of radionuclides introduced into a subject's body. PET generates images by detecting pairs of gamma rays emitted indirectly by a positron-emitting radionuclide. A PET analysis results in a series of thin slice images of the body over the region of interest (e.g., brain, breast, liver, . . . ). These thin slice images can be assembled into a three dimensional representation of the examined area. SPECT is similar to PET, but the radioactive substances used in SPECT have longer decay times than those used in PET and emit single instead of double gamma rays. Although SPECT images exhibit less sensitivity and are less detailed than PET images, the SPECT technique is much less expensive than PET and offers the advantage of not requiring the proximity of a particle accelerator. Actual clinical PET presents higher sensitivity and better spatial resolution than SPECT, and presents the advantage of an accurate attenuation correction due to the high energy of photons; so PET provides more accurate quantitative data than SPECT. Planar scintigraphy (PS) is similar to SPECT in that it uses the same radionuclides. However, PS only generates 2D-information.
- SPECT produces computer-generated images of local radiotracer uptake, while CT produces 3-D anatomic images of X ray density of the human body. Combined SPECT/CT imaging provides sequentially functional information from SPECT and the anatomic information from CT, obtained during a single examination. CT data are also used for rapid and optimal attenuation correction of the single photon emission data. By precisely localizing areas of abnormal and/or physiological tracer uptake, SPECT/CT improves sensitivity and specificity, but can also aid in achieving accurate dosimetric estimates as well as in guiding interventional procedures or in better defining the target volume for external beam radiation therapy. Gamma camera imaging with single photon emitting radiotracers represents the majority of procedures.
- In a preferred embodiment, the radionuclide is detectable by SPECT or an hybrid SPECT/CT.
- The radionuclide may be selected in the group consisting of technetium-99m (99mTc), gallium-67 (67Ga), gallium-68 (68Ga) yttrium-90 (90Y), indium-111 (111In), rhenium-186 (186RE), flourine-18 (18F), copper-64 (64Cu) or thallium-201 (201TI).
- A preferred radionuclide is technetium-99m (99mTc).
- Labeled CD31shed Ligand
- The present invention thus particularly relates to a labeled CD31shed ligand comprising a CD31shed ligand and at least one imaging label.
- The CD31shed ligand and the imaging label are as defined above in the sections of the same name.
- The radiochemical specific activity of labeled CD31shed ligand is preferably greater than 70 GBq/pmol, more preferably greater than 80 GBq/pmol, more preferably greater than 90 GBq/pmol, for example greater than 100 GBq/pmol.
- The labeled CD31shed ligand is preferably stable.
- The stability of the labeled CD31shed ligand may be assessed in vitro and/or in vivo by any method well known by the skilled person, for example by determining radiochemical purity (RCP).
- The radiochemical purity (RCP) may be assessed by high performance liquid chromatography (HPLC) and/or instant thin layer chromatography (ITLC), preferably using both methods.
- For example, the in vitro stability may be assessed after incubation of the labeled CD31shed ligand in vitro in plasma, preferably in human plasma at 37° C., for example for at least 1 hour, at least 2 hours, at least 3 hours or at least 4 hours.
- For example, the in vivo stability may be assessed in a sample of human or non-human mammal urine, for example of rat urine, after administration of the labeled CD31shed ligand in said human or non-human mammal.
- The in vitro and/or in vivo RCP of the labeled CD31shed ligand is preferably greater than 80%, preferably greater than 85%, for example greater than 89%.
- The biodistribution and specific uptake of the labeled CD31shed ligand by activated platelets, endothelial cells and leukocytes may be assessed in an inflammation model, for example in a rat model of heart inflammation, brain inflammation or vascular inflammation, such as the experimental abdominal aorta aneurysm (AAA) induced by local infusion of elastase and followed by intravenous injection of a periodontal bacterium present in human AAA and known to induce AAA inflammation. For example, immediately after intravenous injection of the labeled CD31shed ligand, sequential whole-body acquisitions (for example every 10 minutes for the first hour) are performed, for example using a hybrid SPECT/CT camera (NanoSPECT/CT, Bioscan Inc.).
- The binding of the labeled CD31shed ligand to plasma proteins is preferably low, for example lower than 10%, more preferably lower than 5% after 4 hours of incubation in human plasma at 37° C.
- The low binding to plasma proteins may be assessed by any method well known by the skilled person, such as size exclusion chromatography, for example after incubation of the labeled CD31shed ligand in vitro in plasma, preferably in human plasma, at 37° C., for example for at least 1 hour, at least 2 hours, at least 3 hours or at least 4 hours.
- The CD31shed ligand and the imaging label may be linked covalently or non-covalently.
- The CD31shed ligand and the imaging label are preferably linked non-covalently.
- When the CD31shed ligand comprises a chelating agent, the CD31shed ligand is preferably linked to the imaging label via said chelating agent, and preferably non covalently.
- The labeled CD31shed ligand is preferably a radiolabeled CD31shed ligand.
- A preferred labeled CD31shed ligand thus comprises a CD31shed ligand and at least one radionuclide.
- In one preferred embodiment of the invention, the labeled CD31shed ligand comprises a peptide of sequence SEQ ID NO: 6 consisting of D-enantiomer amino acids as CD31shed ligand and 99mTc as a radionuclide.
- The labeled CD31shed ligand may additionally comprise at least one co-ligand, i.e. one or more ligands coupled to the CD31shed ligand,
- The co-ligand(s) is/are preferably used to stabilize the imaging label binding to the CD31shed ligand.
- For example, the co-ligand may be tricine, EDDA (ethylendiaminediacetic acid) (EDDA), aminocarboxylate, phosphine or pyridine.
- In on embodiment, the labeled CD31shed ligand comprises both tricine and EDDA as co-ligands, for example when the radionuclide is 99mTc.
- When at least one co-ligand is used, the labeled CD31shed ligand comprises or consists of a complex comprising said co-ligand(s), said CD31shed ligand and said radionuclide.
- In one embodiment of the invention, the CD31shed ligand is the peptide of sequence SEQ ID NO: 6 consisting of D-enantiomer amino acids coupled with HYNIC via a spacer as defined above.
- A preferred labeled CD31shed ligand, referred to as 99mTc-HYNIC-P8RI, comprises:
- the compound of formula:
- and
- the radionuclide 99mTc.
- HYNIC forms a 99mTc-N bond between technetium and the hydrazine moiety of HYNIC.
- The labeled CD31shed ligand can be prepared by conventional methods perfectly known by a man skilled in the art.
- In the methods and uses described herein, the labeled CD31shed ligand may be used per se or as a pharmaceutical composition as defined below.
- The methods and uses described herein may be performed by using a kit as defined below.
- Labeled CD31shed Ligand for Use as a Molecular Imaging Agent
- The present invention also relates to the use of a labeled CD31shed ligand as defined above as a molecular imaging agent for imaging inflammation sites.
- The present invention thus also relates to a labeled CD31shed ligand as defined above for use as a molecular imaging agent for imaging of inflammatory sites.
- The present invention particularly relates to a labeled CD31shed ligand as defined above for use as a molecular imaging agent in an in vivo method of detecting, more particularly imaging, inflammatory sites.
- In particular, the present invention relates to a labeled CD31shed ligand for use as defined above, in a method, preferably an in vivo method, for determining whether a subject suffers from an inflammatory condition, is at risk of having an inflammatory condition or is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment or for monitoring the efficacy of a treatment of an inflammatory condition.
- The invention also relates to a labeled CD31shed ligand for use as defined above, wherein the presence, localization and/or amount of CD31shed is determined. The labeled CD31shed ligand indeed binds to CD31shed.
- The presence, localization and/or amount of CD31shed is determined by the presence, localization and/or amount of the labeled CD31shed ligand, i.e. of the signal detected corresponding to the imaging label of said labeled CD31shed ligand.
- The presence, localization and/or amount of the labeled CD31shed ligand may be determined by planar scintigraphy (PS), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), an hybrid SPECT/CT or their combinations.
- The labeled CD31shed ligand is preferably used or administered intravenously.
- The labeled CD31shed ligand is preferably used or administered in an amount sufficient to obtain a detectable signal, in particular one injected intravenously.
- The signal corresponding to the imaging label of the labeled CD31shed ligand is preferably detected immediately after the administration of the labeled CD31shed ligand.
- The signal may be detected in the entire body of the subject or in only one part of the subject (particularly in only one part of the body of the subject).
- The present invention thus particularly relates to a labeled CD31shed ligand as defined above for use in a method for detecting, more particularly imaging, inflammation sites, wherein said method comprises:
-
- administering said labeled CD31shed ligand to the subject, and
- imaging said subject or at least one part of the body of said subject, thereby detecting the binding of the labeled CD31shed ligand to CD31shed in said subject or in said part of the body of the subject.
- The present invention thus particularly relates to a labeled CD31shed ligand as defined above for use in a method for determining whether a subject suffers from an inflammatory condition, is at risk of having an inflammatory condition or is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment or for monitoring the efficacy of a treatment of an inflammatory condition, wherein said method comprises:
-
- administering said labeled CD31shed ligand to the subject, and
- imaging said subject or at least one part of the body of said subject, thereby detecting the binding of the labeled CD31shed ligand to CD31shed in said subject or in said part of the body of the subject.
- The molecular imaging agent of the invention represents a powerful tool for diagnosing or assessing an inflammatory condition associated with CD31shed.
-
- a) Determining if a subject suffers from an inflammatory or is at risk of suffering from an inflammatory condition
- In a method for determining whether a subject suffers from an inflammatory condition or is at risk of suffering from an inflammatory condition, the subject to be diagnosed is suspected to suffer or be likely to suffer from an inflammatory condition or suffers from an inflammatory condition. The method can indeed be performed to confirm that the subject suffers from an inflammatory condition and/or to specify the kind of inflammatory condition.
- The presence, localization and/or amount of CD31shed may indicate that the subject suffers from an inflammatory condition.
- The localization of CD31shed may further indicate the kind of inflammatory condition.
- The amount of CD31shed may further indicate the severity of the inflammation condition.
- The presence, localization and/or amount of CD31shed may be compared to a reference value or a control biological image. When the reference value or the control biological sample corresponds to a healthy subject, in particular a subject that does not suffer from an inflammatory condition or a panel of healthy subjects, a presence, localization and/or amount of CD31shed detected in the biological sample that is greater than those of reference value or of the control image indicates that the subject suffers or, is at risk of having an inflammatory condition.
-
- b) Determining the risk of recurrence of an inflammatory condition after an anti-inflammatory treatment
- The methods and uses according to the invention can also be used to follow the risk of recurrence of an inflammatory condition after an anti-inflammatory treatment. In particular, they can be used to monitor the subject after an anti-inflammatory treatment. For example, this can be achieved by repeating the method at least one time, preferably two times after the end of said treatment, in order to determine the presence, localization and/or amount of CD31shed. An increased presence, localization and/or amount of CD31shed may indicate a high risk of recurrence of an inflammatory condition after an anti-inflammatory treatment. A stable or a decreased presence, localization and/or amount of CD31shed may indicate a low risk of recurrence of an inflammatory condition after an anti-inflammatory treatment. For example, an image of a biological sample and/or of the subject or at least one part of the subject is generated at the end of the treatment and at least one time after treatment. Comparison of the images at the end and after treatment allows the risk of recurrence of an inflammatory condition after an anti-inflammatory treatment to be monitored.
-
- c) Monitoring the response to a treatment of a subject suffering from an inflammatory condition
- The methods and uses according to the invention can also be used to monitor the response to a treatment of a subject suffering from an inflammatory condition. For example, this can be achieved by repeating the method at least two times, for example one time before treatment and at least two times during the treatment, or at least two times during the treatment. For example, an image of a biological sample and/or of the subject or at least one part of the subject is generated before treatment and at least one time during the treatment, for example with an anti-inflammatory treatment. Comparison of the images before and during treatment allows the response of the subject to that particular treatment to be monitored.
- An increased presence, localization and/or amount of CD31shed may indicate that the treatment is not or not any more efficient. A stable or a decreased presence, localization and/or amount of CD31shed may indicate that the treatment is efficient.
- The expression “monitoring the response to a treatment” and “monitoring the efficacy of a treatment” are herein synonymous.
- Said treatment may be a curative or preventive treatment.
- Said treatment may comprise or consist in administering at least one anti-inflammatory agent, at least one immunosuppressant, at least one probiotic (i.e. live microorganisms that may confer a health benefit on the subject), at least one antibiotic or their combinations.
- Method Using a Labeled CD31shed Ligand as a Molecular Imaging Agent
- The present invention also relates to a method for imaging of inflammation sites using a labeled CD31shed ligand as defined above.
- The present invention also relates to a method, preferably an in vitro method, for determining whether a subject suffers from an inflammatory condition, is at risk of having an inflammatory condition or is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment or for monitoring the efficacy of a treatment of an inflammatory condition in a subject, wherein said method comprises detecting the presence of CD31shed on the surface of cells with a labeled CD31shed ligand as defined above in a biological sample of the subject.
- The cells are preferably platelets, leukocytes and/or endothelial cells.
- By “biological sample”, it is herein meant any sample able to contain endothelial cells, platelets or leukocytes, such as a blood sample or fraction thereof (for example a thrombus) or a tissue sample, for example a biopsy.
- The method may comprise a first step of providing a biological sample from the subject.
- The present invention also relates to a method as defined above, wherein the detection of CD31shed on the surface of the cells in said biological sample indicates that the subject suffers, is at risk of having or developing an inflammatory condition or is at risk of recurrence of an inflammatory condition.
- The present invention also relates to a method as defined above, wherein the amount of CD31shed detected on the surface of the cells in said biological sample is compared to a reference value or a control biological sample. When the reference value or the control biological sample corresponds to a healthy subject, in particular a subject that does not suffer from an inflammatory condition or a panel of healthy subjects, an amount of CD31shed detected in the biological sample that is greater than those of reference value or of the control biological sample indicates that the subject suffers, is at risk of having or developing an inflammatory condition or is at risk of recurrence of an inflammatory condition.
- The present invention also relates to a method as defined above, wherein an increased amount of CD31shed detected on the surface of the cells in said biological sample by comparison to the amount detected in a biological sample before treatment or earlier during treatment indicates that said treatment is not efficient and/or wherein a stable or a decreased amount of CD31shed detected on the surface of the cells in said biological sample by comparison to the amount detected in a biological sample before treatment or earlier during treatment indicates that said treatment is efficient.
- Said method may further comprise determining the amount of CD31shed on the surface of cells.
- The detection of CD31shed on the surface of the cells in said biological sample is preferably carried out by imaging techniques.
- The step of detection as mentioned above comprises contacting the biological sample of the subject with a labeled CD31shed ligand, preferably an effective amount of a labeled CD31shed ligand, as a molecular imaging agent.
- The present invention also relates to a method as defined above, wherein said method comprises:
-
- contacting a biological sample of the subject with a labeled CD31shed ligand, and
- detecting the labeled CD31shed ligand bound to CD31shed, thereby detecting the presence of CD31shed on the surface of cells in the biological sample.
- The contact is preferably carried out under conditions that allow the molecular imaging agent (1) to reach the cells of the subject that may express CD31shed (preferably endothelial cells, platelets and/or leukocyte) and (2) to interact with such CD31shed, so that the interaction results in the binding of the molecular imaging agent to the CD31shed. After contact with the labeled CD31shed ligand and after sufficient time has elapsed for the interaction to take place, the molecular imaging agent bound to CD31shed present in the subject sample is detected by a molecular imaging technique as disclosed above.
- An “effective amount” is an amount sufficient to allow the molecular imaging agent to complete these three conditions of (1) reaching the cells, (2) interacting with CD31shed and (3) being detected.
- Method of Treatment of an Inflammation Condition
- The present invention also relates to a method for preventing and/or treating an inflammatory condition in a subject in need thereof, wherein said method comprises,
-
- performing a method as defined above for determining whether a subject suffers from an inflammatory condition, is at risk of having an inflammatory condition or is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment or for monitoring the efficacy of a treatment of an inflammatory condition in a subject,
- when the subject is determined to suffer from an inflammatory condition, to be at risk of having an inflammatory condition or to be at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment or if the treatment is not efficient, administering to said subject a suitable treatment.
- Said suitable treatment may comprise or consist in administering at least one anti-inflammatory agent, at least one immunosuppressant, at least one probiotic (i.e. live microorganisms that may confer a health benefit on the subject), at least one antibiotic, at least one CD31shed ligand linked to an active ingredient or their combinations.
- The present invention also relates to a method for preventing and/or treating an inflammatory condition in a subject in need thereof, wherein said method comprises administering to said subject a CD31shed ligand linked to an active ingredient.
- The active ingredient is for example a drug, such as an anti-inflammatory agent. The CD31shed ligand is thereby used as a drug targeting agent and allows improving the effect of said drug.
- Pharmaceutical Composition Comprising the Molecular Imaging Agent
- The pharmaceutical composition according to the invention comprises at least one labeled CD31shed ligand and at least one pharmaceutically acceptable carrier.
- As used herein, the term “pharmaceutically acceptable carrier” refers to a carrier medium which does not interfere with the effectiveness of the biological activity of the active ingredient, i.e. the molecular imaging agent, and which is not excessively toxic to the subject at the concentration(s) at which it is administered. This term includes solvent(s), dispersion medium/media, coating(s), antibacterial and/or antifungal agent(s), isotonic agent(s), adsorption delaying agent(s) and their combinations. The use of such medium/media and/or agent(s) for pharmaceutically active substance(s) is well known in the art.
- The pharmaceutical composition may be administered by injection. For administration by injection, the pharmaceutical composition comprising the molecular imaging agent may be formulated as sterile aqueous or non-aqueous solution or alternatively as sterile powder for the extemporaneous preparation of a sterile injectable solution. The pharmaceutical composition should be stable under the conditions of manufacture and storage, and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- Pharmaceutically acceptable carrier(s) for administration by injection are solvent(s) or dispersion medium/media, such as aqueous solution(s) (e.g., Hank's solution, alcoholic/aqueous solution or saline solution), and non-aqueous carrier(s) (e.g. propylene glycol, polyethylene glycol, vegetable oil and injectable organic esters such as ethyl oleate). The injectable pharmaceutical composition may also contain parenteral vehicle(s) (such as sodium chloride and Ringer's dextrose) and/or intravenous vehicle(s) (such as fluid and nutrient replenishers); as well as other conventional, pharmaceutically acceptable, non-toxic excipient(s) and additive(s) including salt(s), buffer(s) and preservative(s) such as antibacterial and/or antifungal agent(s) (e.g. parabens, chlorobutanol, phenol, sorbic acid, thirmerosal and the like). Prolonged absorption of the injectable composition can be brought about by adding agents that can delay absorption (e.g. aluminum monostearate and/or gelatin). The pH and concentration of the various components can readily be determined by those skilled in the art.
- The sterile injectable solution may be prepared by incorporating the active compound(s), i.e. the molecular imaging agent, and other ingredient(s) in the required amount of an appropriate solvent and then by sterilizing the resulting mixture, for example, by filtration and/or irradiation.
- In general, the dosage of the molecular imaging agent (or pharmaceutical composition comprising thereof) will vary depending on considerations such as age, sex and weight of the subject, as well as the particular inflammatory condition suspected to affect the patient, the extent of the disease, the tissue(s) of the body to be examined and/or the sensitivity of the imaging label. Factors such as contraindications, therapies, and other variables are also to be taken into account to adjust the dosage of molecular imaging agent to be administered. This, however, can be readily achieved by a trained physician.
- In general, one suitable dose of molecular imaging agent, i.e. of labeled CD31shed ligand, or a pharmaceutical composition comprising thereof, corresponds to the lowest amount of molecular imaging agent or pharmaceutical composition that is sufficient to allow molecular imaging of any relevant CD31shed present in the subject. To minimize this dose, it is preferred that administration be intravenous, intramuscular, intraperitoneal or subcutaneous, and preferably proximal to the site to be examined.
- Kits
- The present invention also provides a kit comprising material(s) useful for carrying out the methods and uses of the invention.
- In certain embodiments, the kit comprises at least one CD31shed ligand as above described and at least one imaging label, preferably at least one radionuclide, and, optionally, instructions for associating said CD31shed ligand and said imaging label, preferably radionuclide, to form a labeled CD31shed ligand according to the invention.
- The radionuclide is preferably a short-lived radionuclide, such as technetium-99m (99mTc), gallium-67 (67Ga), yttrium-90 (90Y), indium-111 (111In), rhenium-186 (186Re), and thallium-201 (201TI), more preferably 99mTc.
- In addition, the kit may further comprise at least one co-ligand, such as tricine and/or ethylendiaminediacetic acid (EDDA).
- In addition, the kit may further comprise one or more of: labelling buffer, labelling reagent, purification buffer, purification reagent, purification means, injection medium, and/or injection reagent. Protocols for using these buffer(s), reagent(s) and/or means for performing different steps of the preparation procedure and/or administration may be included in the kit.
- The different components included in the kit may be supplied in a solid (e.g. lyophilized) or liquid form.
- The kit may optionally comprise different containers (e.g. vial, ampoule, test tube, flask or bottle) for each individual component. Each component will generally be suitable as aliquoted in its respective container or provided in a concentrated form. Other containers suitable for conducting certain steps of the preparation methods may also be provided. The individual containers of the kit are preferably maintained in close confinement for commercial sale.
- In certain embodiments, the kit further comprises instructions for using its components for the imaging of an inflammatory condition as described herein, and in particular for determining whether a subject suffers from, is at risk of having or developing an inflammatory condition or is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment, as described herein.
- Instructions for using the kit according to the invention may comprise instructions for preparing labeled CD31shed ligand from the CD31shed ligand and the imaging label, instructions concerning dosage and mode of administration of the molecular imaging agent thereby obtained, instructions for performing the detection of CD31shed, and/or instructions for interpreting the results obtained. A kit may also contain a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products.
- The present invention will be further illustrated in view of the following examples and figures.
- All references cited herein, including journal articles or abstracts, published or unpublished patent application, issued patents or any other references, are entirely incorporated by reference herein, including all data, tables, figures and text presented in the cited references.
-
FIG. 1 : Radio high performance liquid chromatography (HPLC) of 99mTc-HYNIC-P8RI with tricine (A) and tricine/EDDA as coligands (B). HPLC analysis of the acetonitrile fraction shows a major specie (Tr=10.1 min) with tricine/EDDA contrary to the multiple species profile with tricine. -
FIG. 2 : Radio-HPLC stability study of 99mTc-HYNIC-P8RI with tricine/EDDA as coligands. A: plasma stability after 4 h of incubation in human plasma. B: Radio-HPLC chromatogram of urine collected in arat bladder 1 hour after injection of 74 MBq of 99mTc-HYNIC-P8RI with tricine/EDDA as coligands. For A and B, peak in the acetonitrile fraction (Tr=10.1 min) corresponds to the initial specie with no signs of degradation. -
FIG. 3 : SPECT/CT images of [99mTc]EDDA/HYNIC-P8RI in a male wistar rat with an abdominal aortic aneurysm (AAA) receiving injection of Porphyromonas gingivalis weekly. Images were acquired 30 min after a tracer injection of 74 MBq and 21 days after AAA surgery. The axial (A), coronal (B) and sagittal (C) planes of the abdominal region are shown. It is observed the tracer elimination via kidneys (white arrows in B) and the bladder (white arrow in C). Focal uptake of [99mTc]EDDA/HYNIC-P8RI can be observed at the location of the AAA (black arrows in A, B, C). -
FIG. 4 : Comparison of average counts ratio between right hindlimb and left hindlimb measured in the same region of the thigh for technetium-99m radiolabeled mertiatide (n=3) and P8RI injected rats (n=3), in a model of right hindlimb inflammation. Briefly, turpentine oil was injected intramuscularly in Wistar rats right hindlimb and the contralateral thight was injected similarly and simultaneously with saline. SPECT/CT acquisitions were performed 48 hours later and 30 min after injection of 80 MBq of [99mTc]-HYNIC-PEGS-P8RI or [99mTc]-mertiatide. Comparison between the two groups was realized using a Mann-Withney U test, a p value of less than 0.05 was considered significant. - SEQ ID NO: 1 corresponds to the sequence of human CD31.
- SEQ ID NO: 2 corresponds to the sequence LAPWKK of a 6 amino acid peptide derived from human or murine CD31.
- SEQ ID NO: 3 corresponds to the sequence VRVFLAPWKK of a 10 amino acid peptide derived from murine CD31, also called PepReg CD31.
- SEQ ID NO: 4 corresponds to the sequence VRVILAPWKK of a 10 amino acid peptide derived from human CD31.
- SEQ ID NO: 5 corresponds to the sequence RVFLAPWK of a 8 amino acid peptide derived from murine CD31, also called P8F.
- SEQ ID NO: 6 corresponds to the sequence kwpalfvr of a 8 amino acid peptide, also called P8RI, having the inverted sequence of SEQ ID NO: 5 and consisting of D-amino acids.
- SEQ ID NO: 7 corresponds to the sequence RVILAPWK of a 8 amino acid peptide derived from human CD31.
- SEQ ID NO: 8 corresponds to the sequence kwpalivr of a 8 amino acid peptide having the inverted sequence of SEQ ID NO: 7 and consisting of D-amino acids.
- SEQ ID NO: 9 corresponds to the sequence of murine CD31.
- SEQ ID NO: 10 corresponds to the sequence of bovine CD31.
- SEQ ID NO: 11 corresponds to the sequence of pig CD31.
- SEQ ID NO: 12 corresponds to the amino acids 579 to 601 of sequence SEQ ID NO: 1.
- Sequences SEQ ID NO: 13 to 74 are as defined above.
- Reagents were purchased from Sigma-Aldrich Corporation except when otherwise stated and used as received. P8RI (H-kwpalfvr-OH) was synthetized on solid phase with a purity>85% analyzed by RP-HPLC/MS. HYNIC- P8RI was prepared by solid phase peptide synthesis using Fmoc chemistry (yield after RP-HPLC purification 52%, purity by RP-HPLC 96%).
- Na99mTcO4 − was obtained from a commercial 99Mo/99mTc generator (TEKCIS®, Iba molecular, France).
- A Dionex Ultimate 3000 system coupled to a Berthold radiometric detector was used for RP-HPLC analysis. A ACE 3 C18, 3 μ, 100 Å, 150×4.6 mm column, at a flow rate of 1 mUmin and with UV detection at 220 nm, was employed with the following mobile phases, A: 0.1% TFA/water), B Acetonitrile (ACN). Gradient was: 0-2 min 23% B, 2-20 min 23-50% B, 20-23 min 50-100% B, 23-25 min 100-23% B, 25-28 min 23% B.
- TLC was performed using a radiochromatogaph (MiniGita, Raytest, Germany). Stationary phase was silica gel (ITLC-SG, Agilent technologies, USA) and different mobile phases were employed. MEK was used to determine the amount of free 99mTcO4 − (Rf=1), Anticoagulant Citrate Dextrose Solution (ACD-A, Baxter International, USA) to determine non-peptide-bound 99mTc-coligands and 99mTcO4 − (Rf=1), 60% ACN for 99mTc-colloid (Rf =0)
- In a rubber-sealed N2 purged
vial 20 μg of HYNIC- P8RI were incubated with 500 μL of a tricine solution (40 mg/mL inPBS 1× buffer pH 7.2), 80 μL of a tin(II) solution (1 mg/mL in HCl 0.1N), 1 GBq 99mTcO4- eluate and PBS qs a 3 mL total volume for 30 min at room temperature (RT). - In a rubber-sealed N2 purged
vial 20 μg of HYNIC- P8RI were incubated with 500 μL of a EDDA solution (20 mg/mL in NaOH 0.1N), 80 μL of a tin(II) solution (1 mg/mL in HCl 0.1N), 1 GBq 99mTcO4− eluate andPBS 1× qs a 3 mL total volume for 30 min at RT. - Same procedure than tricine as coligand except that 500 μL of a EDDA solution (20 mg/mL in NaOH 0.1N) was added in the reaction vial and heated for 10 min at 100° C.
- Purification was realized using C18 Sep-Pak cartridge (Sep-Pak C18 Plus Light Cartridge, Waters, USA) preactivated with 10 mL of ethanol followed by 10 mL of water and 5 mL of air. After passing the radiolabeling preparation through the cartridge and washing it with 8 mL of water, the radiolabeled peptide was eluted with 80% ACN which was then evaporated under vacuum.
- Stability of 99mTc complexes was assessed in fresh human plasma at 37° C. after 0 min, 30 min, 1 hour, 2 hours and 4 hours of incubation at a concentration of 100 pmol/mL. Next, plasma samples were precipitated with methanol and centrifuged (20000 g, 10 min). Supernatants were collected and filtered (Millex-GV 0.22 μm PVDF, Merck Millipore, Germany) then assessed by radio-HPLC.
- 74 MBq of 99mTc-HYNIC-P8RI (obtained with tricine/EDDA as coligands) was injected to a male wistar rat. After one hour, rat was sacrificed and urine was directly collected from the bladder using a syringe and analyzed by radio-HPLC after a 0.22 μm filtration (Millex-GV 0.22 μm PVDF, Merck Millipore, Germany).
- Protein binding of the purified radiolabeled peptide was determined after 0 min, 30 min, 1 hour, 2 hours and 4 hours of incubation in fresh human plasma at 37° C. and analyzed after size exclusion chromatography (illustra Microspin G-50 Columns, Sephadex G-50, GE Healthcare, UK). G-50 columns were prespun at 2000×g for 1 min then 20 μL of mixture was added and the column was centrifuged at 2000×g for 2 min. Protein binding of the radiolabeled peptide was estimated by measuring columns and eluates in a gamma-counter (Cobra II, Packard Bioscience). In the same time, radiolabeled peptide was incubated for 1 h in
PBS 1× at 37° C. as a control. - 8.1. Abdominal Aorta Aneurysm (AAA) Model
- Rat model of vascular inflammation that has been set up at the laboratory: the experimental abdominal aorta aneurysm (AAA) induced by local infusion of elastase and followed by intravenous injection of a periodontal bacterium present in human AAA (Porphyromonas gingivalis) and known to induce AAA inflammation (Delbosc et al., 2011, PLoS ONE 6(4): e18679. doi:10.1371/journal.pone.0018679).
- 8.2. Hindlimb Inflammation Model
- Rat model of hindlimb inflammation was induced by intramuscular injection of turpentine oil (150 μl) in the right hindlimb, whereas a saline solution (150 μl) was injected in the left hindlimb (contralateral control).
- Immediately after intravenous injection via the penis vein of 74 MBq of radiolabelled HYNIC-P8RI (obtained using Tricine/EDDA), sequential whole-body acquisitions (every 10 minutes for the first hour) were performed with a hybrid SPECT/CT camera (NanoSPECT/CT, Bioscan Inc.) dedicated to small animals.
- Acquisitions were performed 30 min after injection of 80 MBq of 99mTc-HYNIC-P8RI (obtained with tricine/EDDA as coligands) and 99mTc-mertiatide, respectively.
- 6-Hydrazinopyridine-3-carboxylic acid (HYNIC) was coupled to the N-terminal amino-acid of the P8RI peptide via a 3(PEG) spacer to obtain HYNIC-P8RI.
- HYNIC-P8RI was then labeled at high specific activities (>71 GBq/μmol) using tricine, EDDA or Tricine/EDDA as coligands. Labelling yields varied from 65.5% to 98.3% as shown in Table 2. The tricine/EDDA exchange labeling strategy was chosen because of high labeling yield and resulting in a single major specie as analyzed by HPLC (see
FIG. 1 ). -
TABLE 2 Labelling yields of 99mTc-HYNIC-P8RI using different coligands Co-ligand N yield(%) SD (%) Tricine 3 98.3 0.5 EDDA 3 65.5 7.3 Tricine/EDDA 3 93.8 2.8 - In vitro stability in human plasma revealed a high stability of the 99mTc complex with no significant release of radiolabeled impurities or radiolabeled peptide degradation. The RCP (radiochemical purity) was superior to 89% after 4 h of incubation (see
FIG. 2 A). In vivo stability study on rat urine by radio-HPLC analysis showed one major species excreted with a retention time corresponding to the injected radiotracer. This result indicates that 99mTc-HYNIC-P8RI may be excreted unchanged (seeFIG. 28 ). - Very low levels of protein binding as determined by size exclusion chromatography (<5% after 4 h incubation) were found using the Tricine/EDDA coligands exchange labelling strategy. This finding suggests that 99mTc-HYNIC-P8RI may be a hydrophilic compound.
- 4. SPECT/CT Imaging—AAA Model
- Representative SPECT and CT images were obtained after an acquisition performed 30 min after injection of 99mTc-HYNIC-P8RI (obtained with tricine/EDDA as coligands) in AAA rat as shown in
FIG. 3 . The pattern of biodistribution indicated almost exclusive renal uptake and excretion. Interestingly, there was a focal uptake of the radiotracer on the aorta pathway corresponding to the location of the AAA. - 5. X ray CT Scanner, SPECT and SPECT/CT Acquisitions—Right Hindlimb Inflammation model
- 99mTc- HYNIC-P8RI was further assessed in a rat model of right hindlimb inflammation using turpentine oil.
- Mertiatide is a non-specific marker of renal function and was used as a negative control, because of its biodistribution pattern close to peptide P8RI (in particular, low molecular weight and quick clearance).
- In this model, the technetium-99m radiolabeled P8RI uptake ratio between the turpentine oil injected hindlimb and the saline injected hindlimb was higher compared to the control group injected with technetium-99m radiolabeled mertiatide, thereby confirming the specific binding of P8RI to inflammatory sites (see
FIG. 4 ). - The RCP of [99mTc]EDDA/HYNIC-P8RI was >93% (HPLC and ITLC) without any purification and the specific activity was >71 GBq/pmol. There was no significant release of degraded radiolabelled peptide (RCP>89%) and the radiotracer binding to plasma proteins was very low (<5% after 4 h incubation). In vivo, blood clearance of the tracer was almost exclusively renal with a peak activity in kidneys and bladder 1 h after injection, corresponding to the unaltered form of the peptide on HPLC. In addition, 99mTc-HYNIC-P8RI uptake by AAA was detectable from 30 min after injection in animals and associated with activated platelets and leukocytes on immunohistochemistry. 99mTc-HYNIC-P8RI was also specifically detected in inflammatory sites in a model of right hindlimb inflammation. By specifically targeting activated cells involved in inflammation expressing truncated CD31 (CD31shed) and with a rapid blood clearance, radiolabelled P8RI constitutes a useful novel approach in inflammation imaging.
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/305,966 US20210347890A1 (en) | 2016-05-03 | 2021-07-19 | Cd31shed as a molecular target for imaging of inflammation |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16305516 | 2016-05-03 | ||
EP16305516.3 | 2016-05-03 | ||
PCT/EP2017/060574 WO2017191214A1 (en) | 2016-05-03 | 2017-05-03 | Cd31shed as a molecular target for imaging of inflammation |
US201816098488A | 2018-11-02 | 2018-11-02 | |
US17/305,966 US20210347890A1 (en) | 2016-05-03 | 2021-07-19 | Cd31shed as a molecular target for imaging of inflammation |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2017/060574 Division WO2017191214A1 (en) | 2016-05-03 | 2017-05-03 | Cd31shed as a molecular target for imaging of inflammation |
US16/098,488 Division US11098124B2 (en) | 2016-05-03 | 2017-05-03 | CD31 shed as a molecular target for imaging of inflammation |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210347890A1 true US20210347890A1 (en) | 2021-11-11 |
Family
ID=56096588
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/098,488 Active US11098124B2 (en) | 2016-05-03 | 2017-05-03 | CD31 shed as a molecular target for imaging of inflammation |
US17/305,966 Abandoned US20210347890A1 (en) | 2016-05-03 | 2021-07-19 | Cd31shed as a molecular target for imaging of inflammation |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/098,488 Active US11098124B2 (en) | 2016-05-03 | 2017-05-03 | CD31 shed as a molecular target for imaging of inflammation |
Country Status (6)
Country | Link |
---|---|
US (2) | US11098124B2 (en) |
EP (1) | EP3452109A1 (en) |
JP (2) | JP7166512B2 (en) |
CN (1) | CN109310788A (en) |
IL (1) | IL262699B (en) |
WO (1) | WO2017191214A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117567594A (en) * | 2023-11-30 | 2024-02-20 | 北京博奥森生物技术有限公司 | Preparation method of branched polypeptide simulating antigenicity of CD31 linear molecule |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
WO2002010217A2 (en) * | 2000-08-02 | 2002-02-07 | The Johns Hopkins University | Endothelial cell expression patterns |
US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
US9127086B2 (en) * | 2008-06-30 | 2015-09-08 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | CD31 peptides in the treatment of thrombotic and autoimmune disorders |
AU2009265753B2 (en) * | 2008-06-30 | 2016-05-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Detection of shed CD31, diagnosis of atherothrombosis and autoimmune disorders, and methods for analyzing signaling pathways |
JOP20210044A1 (en) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | Anti-cd38 antibodies |
WO2013152919A1 (en) | 2012-04-11 | 2013-10-17 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Detection of platelet-derived shed cd31 |
HUE055593T2 (en) * | 2012-06-19 | 2021-12-28 | Inst Nat Sante Rech Med | Improved cd31 peptides |
KR20180125995A (en) * | 2016-03-21 | 2018-11-26 | 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) | CD31shed agonist for use in the prevention and / or treatment of reperfusion injury |
-
2017
- 2017-05-03 US US16/098,488 patent/US11098124B2/en active Active
- 2017-05-03 JP JP2019510753A patent/JP7166512B2/en active Active
- 2017-05-03 CN CN201780036133.6A patent/CN109310788A/en active Pending
- 2017-05-03 EP EP17719860.3A patent/EP3452109A1/en active Pending
- 2017-05-03 WO PCT/EP2017/060574 patent/WO2017191214A1/en unknown
-
2018
- 2018-10-31 IL IL262699A patent/IL262699B/en unknown
-
2021
- 2021-07-19 US US17/305,966 patent/US20210347890A1/en not_active Abandoned
-
2022
- 2022-03-16 JP JP2022041427A patent/JP2022088462A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL262699B (en) | 2021-08-31 |
US11098124B2 (en) | 2021-08-24 |
CN109310788A (en) | 2019-02-05 |
JP7166512B2 (en) | 2022-11-08 |
JP2022088462A (en) | 2022-06-14 |
EP3452109A1 (en) | 2019-03-13 |
IL262699A (en) | 2018-12-31 |
JP2019524854A (en) | 2019-09-05 |
US20190092858A1 (en) | 2019-03-28 |
WO2017191214A1 (en) | 2017-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8778303B2 (en) | 99mTc-labeled 19 amino acid containing peptide for use as phosphatidylethanolamine binding molecular probe and radiopharmaceutical | |
US11369701B2 (en) | Ri-labeled humanized antibody | |
Ujula et al. | Synthesis, 68Ga labeling and preliminary evaluation of DOTA peptide binding vascular adhesion protein-1: a potential PET imaging agent for diagnosing osteomyelitis | |
IL167518A (en) | Compound binding to leukocytes and medicinal composition containing the compound in labeled state as the active ingredient | |
KR101523686B1 (en) | Molecular probe for imaging islets of langerhans, and use therefore | |
US20210347890A1 (en) | Cd31shed as a molecular target for imaging of inflammation | |
KR101525473B1 (en) | Molecular probe for pancreatic islet imaging and use of said probe | |
US10471162B2 (en) | Collagen targeted imaging probes | |
KR101511660B1 (en) | Peptide derivative and use thereof | |
De et al. | HYNIC and DOMA conjugated radiolabeled bombesin analogs as receptor-targeted probes for scintigraphic detection of breast tumor | |
US20130323171A1 (en) | Radiolabeled bbn analogs for pet imaging of gastrin-releasing peptide receptors | |
US6855308B2 (en) | PACAP compositions and methods for tumor imaging and therapy | |
Luo et al. | Preparation, in vitro and in vivo evaluation of 99mTc-Annexin B1: A novel radioligand for apoptosis imaging | |
US9272054B2 (en) | Agents for the molecular imaging of serine-protease in human pathologies | |
KR20230174243A (en) | Humanized antibodies labeled with β-ray emitting nuclides | |
KR20150102000A (en) | Polypeptide and imaging method | |
Chandra et al. | Synthesis, radiolabeling and biological evaluation of a neutral tripeptide and its derivatives for potential nuclear medicine applications | |
Edwards et al. | Tc-99m-labeled small biomolecules as potential radiopharmaceuticals for infection and inflammation imaging | |
Lee et al. | Radiolabeling, autoradiogram and in vivo Imaging of atherosclerosis-specific peptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BAY, SYLVIE;NICOLETTI, ANTONINO;LE GULUDEC, DOMINIQUE;AND OTHERS;SIGNING DATES FROM 20181101 TO 20181204;REEL/FRAME:056973/0976 Owner name: INSTITUT PASTEUR, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BAY, SYLVIE;NICOLETTI, ANTONINO;LE GULUDEC, DOMINIQUE;AND OTHERS;SIGNING DATES FROM 20181101 TO 20181204;REEL/FRAME:056973/0976 Owner name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BAY, SYLVIE;NICOLETTI, ANTONINO;LE GULUDEC, DOMINIQUE;AND OTHERS;SIGNING DATES FROM 20181101 TO 20181204;REEL/FRAME:056973/0976 Owner name: UNIVERSITE PARIS 13 - PARIS NORD, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BAY, SYLVIE;NICOLETTI, ANTONINO;LE GULUDEC, DOMINIQUE;AND OTHERS;SIGNING DATES FROM 20181101 TO 20181204;REEL/FRAME:056973/0976 Owner name: UNIVERSITE PARIS DIDEROT - PARIS 7, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BAY, SYLVIE;NICOLETTI, ANTONINO;LE GULUDEC, DOMINIQUE;AND OTHERS;SIGNING DATES FROM 20181101 TO 20181204;REEL/FRAME:056973/0976 Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BAY, SYLVIE;NICOLETTI, ANTONINO;LE GULUDEC, DOMINIQUE;AND OTHERS;SIGNING DATES FROM 20181101 TO 20181204;REEL/FRAME:056973/0976 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: UNIVERSITE DE PARIS, FRANCE Free format text: MERGER;ASSIGNOR:UNIVERSITE PARIS DIDEROT - PARIS 7;REEL/FRAME:057998/0128 Effective date: 20200101 |
|
AS | Assignment |
Owner name: UNIVERSITE PARIS CITE, FRANCE Free format text: CHANGE OF NAME;ASSIGNOR:UNIVERSITE DE PARIS;REEL/FRAME:060530/0623 Effective date: 20220304 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |